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Abstract 
 
Kirk M. Habegger 
 
MEMBRANE CHOLESTEROL BALANCE IN EXERCISE AND INSULIN 
RESISTANCE 
 
 Study has shown that plasma membrane (PM) cholesterol and cortical 
filamentous actin (F-actin) influence skeletal muscle glucose transport. Of 
fundamental and clinical interest is whether diabetogenic insults promote 
membrane/cytoskeletal dysfunction amendable for therapy. As exposure to 
excess fatty acid (FA)s induce glucose intolerance by mechanisms imperfectly 
understood, we tested if PM cholesterol/F-actin changes could contribute to FA-
induced glucose transporter GLUT4 dysregulation in skeletal muscle. High-fat 
fed, insulin-resistant animals displayed elevated levels of skeletal muscle PM 
cholesterol and a loss in cortical F-actin, compared to normal-chow fed animals. 
Consistent with a PM cholesterol component of glucose intolerance, human 
skeletal muscle biopsies revealed an inverse correlation between PM cholesterol 
and whole-body glucose disposal. Mechanistically, exposure of L6 myotubes to 
the saturated FA palmitate induced an increase in PM cholesterol that 
destabilized actin filaments and decreased insulin-stimulated PM GLUT4 and 
glucose transport, which could be reversed with cholesterol lowering. Next, study 
tested if the lipid-lowering action of the antidiabetic AMP-activated protein kinase 
vi 
(AMPK) had a beneficial influence on PM cholesterol balance. Consistent with 
AMPK inhibition of 3-hydroxy-3-methylglutaryl CoA reductase, a rate-limiting 
enzyme of cholesterol synthesis, we found that AMPK activation promoted a 
significant reduction in PM cholesterol and amplified basal and insulin-stimulated 
GLUT4 translocation. A similar loss of PM cholesterol induced by β-cyclodextrin 
caused an analogous enhancement of GLUT4 regulation. Interestingly, PM 
cholesterol replenishment abrogated the AMPK effect on insulin, but not basal, 
regulation of GLUT4 translocation. Conversely, AMPK knockdown prevented the 
enhancement of both basal and insulin-stimulated GLUT4 translocation. As a 
whole these studies show PM cholesterol accrual and cortical F-actin loss 
uniformly in skeletal muscle from glucose-intolerant mice, swine, and humans. In 
vivo and in vitro dissection demonstrated this membrane/cytoskeletal 
derangement induces insulin resistance and is promoted by excess FAs. Parallel 
studies unveiled that the action of AMPK entailed lowering PM cholesterol that 
enhanced the regulation of GLUT4/glucose transport by insulin. In conclusion, 
these data are consistent with PM cholesterol regulation being an unappreciated 
aspect of AMPK signaling that benefits insulin-stimulated GLUT4 translocation 
during states of nutrient excess promoting PM cholesterol accrual. 
 
Jeffrey S. Elmendorf, Ph.D., Chair  
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Chapter I 
 
Introduction 
 
 Diabetes is a devastating and costly disease escalating in our country and 
throughout the developed world. This disease currently affects approximately 24 
million individuals in the United States (8% of the population), with Type 2 
diabetics accounting for the vast majority of those afflicted, over 90% 1. In 
addition to those who are already afflicted, there are a staggering 57 million pre-
diabetics who are likely to develop the disease, and the incidence is rising at a 
rate of 1.6 million people per year 1. A well-recognized pathophysiological feature 
of type 2 diabetes (T2D), as well as pre-diabetes, insulin resistance appears to 
drive the progression of this disease and is highly correlated with cardiovascular 
risk factors which often account for the morbidity in these patients 2-5.  
 Although the exact mechanism/signal that elicits insulin-resistance is yet 
to be elucidated, nutritional excess and/or obesity are well-known factors which 
predispose individuals to develop insulin resistance and T2D. While the 
molecular links between obesity and insulin resistance are not well understood; 
increased levels of glucose, insulin, and free fatty acids (FFA)s have all been 
shown to be associated with a diminishment in insulin sensitivity, both in vitro and 
in vivo 6-12. For example, high levels of glucose and lipids may prevent insulin’s 
activation of key signaling intermediates 8, 13. Importantly however, 
pathophysiologic nutrient toxicity appears to occur without altering insulin 
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signaling mechanisms, but rather via profound changes in plasma membrane 
(PM) lipids and cytoskeletal structure 11, 14, 15. Interestingly, glucose toxicity has 
been implicated as the basis of both insulin- and lipid-induced insulin resistance 
12, 16 providing a possible common mechanism, and therefore a common therapy, 
for multiple states of nutritional excess. 
 While the focus of my thesis work is dedicated to the study of PM and 
cytoskeletal dynamics and their influence on glucose transporter GLUT4 
mediated glucose transport, this work builds upon the fundamental findings that 
have been established in the field. As such, the first four sections of this 
introduction will highlight insulin-regulated glucose homeostasis, cellular 
mechanisms of insulin action, insulin stimulated signal transduction, and obesity 
induced defects in insulin resistance; key findings that establish the framework 
for the study of glucose homeostasis and defects leading to insulin resistance. 
 
A. Insulin-regulated glucose homeostasis  
Insulin is a pancreatic hormone that regulates many cellular functions in a 
myriad of tissues throughout the body. A primary function of insulin entails the 
post-prandial regulation of glucose homeostasis. In the post-prandial state, 
elevated glucose levels stimulate the release of insulin from the β-cells of 
pancreatic islets. Once released into the blood stream, insulin acts on the liver, 
adipose tissue and skeletal muscle to clear circulating glucose and restore 
glucose homeostasis. At the liver, insulin binding inhibits hepatic glucose output 
from both glycogenolysis and gluconeogenesis. Conversely, in adipose and 
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striated muscle (skeletal and cardiac) tissues, insulin binding stimulates 
uptake/transport of glucose. The combined suppression of hepatic glucose 
production and export from the liver, and activation of glucose transport into fat 
and muscle by insulin are essential to the normal regulation of glucose 
homeostasis. 
In adipose and striated muscle tissues, insulin mediated glucose uptake is 
contingent on the ability of insulin to stimulate the redistribution of the glucose 
transporter GLUT4 from an intracellular membrane compartment to the PM 17-19. 
A failure in these tissues to respond to insulin stimulation (i.e. insulin resistance) 
is a central component of T2D, obesity, and the metabolic syndrome-X. This 
resistance initially leads to glucose intolerance, compensatory hyperinsulinemia, 
and dyslipidemia. However, as the resistance progresses, the β-cell 
expansion/compensation fails and thus, these cells can no longer secrete 
additional insulin and eventually decline in number. This loss of β-cells and the 
insulin hormone they produce results in frank T2D.  
 At the molecular level, insulin resistance has many facets and varies from 
tissue to tissue. In adipose tissue and skeletal muscle one of the key definitions 
of insulin resistance is a failure to recruit GLUT4 to the PM in response to insulin 
stimulation, while in the setting of normal GLUT4 protein expression. These 
findings argue the importance for elucidating the mechanisms of GLUT4 
mediated glucose transport, in the hopes that one day it will be possible to treat 
insulin resistance at the molecular level. While a complete mechanism linking 
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insulin to GLUT4 translocation and glucose transport has yet to be elucidated, 
significant advances have been made over the last two decades in this regard.  
 The focus of this dissertation was to dissect mechanisms of glucose 
transport regulation in skeletal muscle and to define derangements that 
compromise this system. Therefore, the following sections/subsections will 
provide pertinent information on our current state of knowledge regarding 
regulated glucose transport and insulin resistance in skeletal muscle. It is 
important to note that skeletal muscle is by no means the only tissue involved in 
glucose homeostasis. As such, expanded information on hepatic and/or 
adipocyte insulin action can be found in several detailed reviews on these 
specific topics 20, 21. 
 
B. Cellular mechanisms of insulin action in skeletal muscle 
 On the cellular level, insulin regulates many processes including glucose 
homeostasis. This whole body effect is a combination of both independent and 
interrelated mechanisms in several key systems including liver, skeletal muscle, 
and adipose tissues. In skeletal muscle and adipose tissues, insulin contributes 
to glucose homeostasis by stimulating the trafficking of GLUT4 to the PM, 
facilitating glucose transport. While together these tissues account for over 90% 
of the post-prandial glucose disposal, skeletal muscle is responsible for the vast 
majority 22. In the absence of insulin, GLUT4 primarily resides in intracellular 
membrane pools. The binding of insulin hormone to its receptor stimulates a 
signaling cascade, concluding with the trafficking and subsequent incorporation 
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of GLUT4 containing vesicles into the PM. This exocytotic event is accompanied 
by a slowing of the endocytosis of GLUT4, leading to an accumulation of GLUT4 
at the PM. Altogether these events dispose of excess blood-glucose, an event 
which is essential for maintaining normal glucose homeostasis. 
 To better detail these signaling events, and the subsequent glucose 
transport, the following subsections will provide in-depth analysis of the known 
effectors of insulin-stimulated glucose transport and defects that result in insulin 
resistance and glucose dysregulation. 
 
B.1. Insulin stimulated signal transduction 
 The precise mechanism of action by which insulin stimulates the 
translocation and fusion of GLUT4 vesicles into the PM is a highly coordinated 
and regulated assemblage of signaling networks initiated by the binding of insulin 
to its receptor. The insulin receptor is a member of the protein tyrosine kinase 
(PTK) family of proteins. It is a transmembrane protein comprised of two 
extracellular α-subunits and two β-subunits that consist of the transmembrane 
and intracellular tyrosine kinase domains. The receptor subunits are connected 
by disulphide bonds that link the α-subunits to each other, as well as to the β-
subunits. The signaling cascade is initiated by the binding of insulin to the α-
subunit of the insulin receptor. This binding causes a conformational change in 
the receptor, allowing for the auto-phosphorylation of tyrosine residues on the β-
subunit 23, 24. In the auto-phosphorylated state, the insulin receptor kinase is more 
catalytically active, and rapidly phosphorylates tyrosine residues of the insulin 
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receptor substrates (IRS) as well as additional scaffolding proteins (i.e. Grb2 and 
Shc) 25. The IRS proteins are a class of six cytosolic proteins (IRS1-6) 
characterized by the presence a phospho-tyrosine binding (PTB) and Pleckstrin 
homology (PH) domains. These domains allow the IRS proteins to bind to the 
phospho-tyrosine residues of the β-subunit, leading to subsequent tyrosine 
phosphorylation of the IRS proteins by the receptor kinase. Mechanistic studies 
in transgenic and knockout mice, as well as small interfering RNA (siRNA) 
knockdown studies in L6 myotubes, suggest that it is the IRS1 isoform that is 
responsible for the propagation of this signaling cascade in the context of insulin 
stimulated glucose uptake 26-28. This initial phase in the signaling cascade is also 
subject to negative feedback. The phosphatase activity of protein tyrosine 
phosphatase 1B (PTP1B) and the ubiquitin ligase activity of suppressor of 
cytokine signaling 3 (SOCS3) have both been shown to inactivate the insulin 
receptor and its substrates 25. 
 Following the receptor-mediated tyrosine phosphorylation, IRS1 is 
converted into a suitable docking site for effector proteins containing Src 2 
homology (SH2) domains, which associate with the phosphorylated tyrosine 
residues. The first IRS1 associated SH2 protein to be identified was Class 1A 
phosphatidylinoisitol-3-kinase (PI3K) 29. PI3K exists as a dimer consisting of a 
110-kDa protein (p110) with catalytic activity and an 85-kDa (p85) regulatory 
subunit, which stabilizes and conformationally inhibits the catalytic activity of 
p110. The regulatory subunit contains two SH2 domains which both associate 
with the phosphorylated tyrosine residues of IRS1 30. In the absence of IRS1 
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phospho-tyrosine residues, the p85 subunit inhibits activity of the p110 subunit 
via binding to the p110 subunit by means of a p110 binding domain contained 
near the C-terminus of regulatory subunit. Upon stimulation and subsequent 
phosphorylation of IRS tyrosine residues, SH2 domains of the p85 subunit bind 
to the phospho-tyrosine residues, relieving the p85-mediated inhibition of the 
p110 catalytic subunit 31. In addition to exposing the catalytic site, the N-terminal 
Ras binding domain is also uncovered; bringing the kinase into close proximity 
with the PM. Now catalytically active, the p110 subunit acts on its lipid substrate, 
phosphatidylinositol 4,5 bisphosphate (PIP2), phosphorylating the 3 position of 
the inositol ring to generate phosphatidylinositol 3,4,5 trisphosphate (PIP3) 32. 
 The accumulation of PM PIP3 is an essential node in the insulin regulation 
of GLUT4 translocation, as evidenced by the ablation of GLUT4 and glucose 
uptake in the presence of the PI3K inhibitor wortmannin 33. The generation of this 
membrane lipid provides for docking and activation of downstream effector 
proteins containing PH domains. Important among these effector proteins are Akt 
(also referred to as protein kinase B, PKB) and phosphoinositide-dependent-
kinase-1 (PDK1). Both of these proteins are recruited, via their PH domains, to 
the PM in response to the accumulation of PIP3 34. The activity of the Ser/Thr 
kinase Akt is tightly regulated and highly dependent upon cellular location. The 
activation of Akt results from the recruitment of this kinase from cytosolic pools, 
where it is inactive, to the PM. Once at the PM Akt is phosphorylated on Ser473 of 
its hydrophobic motif (HM) by PDK2 (reviewed in the following reference 35). This 
recently identified enzyme is comprised of the mammalian target of rapamycin 
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(mTOR) in a complex with its regulatory protein, rictor 36, 37, collectively known as 
TORC2. The phosphorylated HM of Akt stabilizes and activates PDK1 via its 
PRK2-interacting fragment (PIF)-pocket, which then phosphorylates Akt on 
Thr308. Following Thr308 phosphorylation, the HM of Akt now prefers association 
with its own PIF-pocket, resulting in dissociation from PDK1 and maximal 
activation of Akt. This activation results in the regulation of many cellular 
processes including those of glucose and lipid metabolism (i.e., regulation of 
glycogen synthase kinase and fatty acid synthase). While three isoforms of Akt 
have been identified (Akt1-3) in mammalian cells; transgenic animal, knockout 
mouse, and siRNA knockdown studies have suggested that it is the Akt-2 isoform 
that is specifically responsible for the transmission of insulin stimulation in 
glucose transport 38-41. 
 While the pivotal role of Akt in insulin-regulated glucose transport has 
been investigated for some time, the identification of the Akt substrate of 160 kDa 
(AS160) in 2002 by Lienhard and colleagues defined a new distal point in the 
canonical insulin signaling pathway. AS160, also known as Tre2/Bub2/Cdc16 
domain family member 4 (TBC1D4), and its closest relative TBC1D1 42; were 
found to contain a Rab-GTPase-activating protein (GAP) domain at the C-
terminus, suggesting a role in the regulation of vesicular trafficking 43. Mutation of 
the Akt target phosphorylation sites (Ser318, Ser588, Thr642, and Ser751) to alanine 
reduced insulin stimulated GLUT4 translocation 44. This study suggested that 
AS160 was responsible for retention of intracellular GLUT4 vesicles in the 
absence of insulin stimulation and when phosphorylated, the inhibition was 
9 
released allowing for trafficking of these vesicles to the PM. Furthermore, it was 
shown that an intact GAP domain was necessary to maintain the reduction in  
insulin-stimulated GLUT4 translocation 44. Additional studies utilizing siRNA 
knockdown of AS160 confirmed the role of AS160 in GLUT4 vesicular retention 
45. As virtually all vesicle trafficking systems are regulated by small GTP-binding 
proteins 46, (such as Rabs), it is likely that a target of AS160/TBC1D1 specifically 
regulates the translocation of GLUT4-containing vesicles. To identify the target/s 
of AS160/TBC1D1 multiple groups have utilized immunoprecipitation of GLUT4 
vesicles from 3T3-L1 adipocytes followed by mass spectrometry. These studies 
have identified Rab10, Rab11 and Rab14 as targets, with Rab10 being the most 
likely candidate 47, 48. siRNA knockdown studies further confirmed the role Rab10 
as an AS160 target and effector of GLUT4 translocation 49, 50. In muscle cell lines 
the target of TBC1D1 is less well elucidated; however, emerging data suggest 
that the Rab8a and the Rab11 effector Rip11 may be the AS160/TBC1D1 target 
responsible for GLUT4 translocation 51, 52. 
 While the canonical insulin signaling network described above appears to 
be a dominant regulator; there are at least two other pathways of interest with 
regards to insulin-mediated regulation of GLUT4. The first of these pathways is 
referred to as the atypical protein kinase C (aPKC) cascade. In addition to 
activating Akt, insulin-stimulated PDK1 is known to activate the aPKC family 
members PKCλ and PKCζ 53. Once activated by PDK1 these Ser/Thr kinases 
stimulate GLUT4 translocation by promoting the association of Rab4, the 
microtubule motor protein KIF3, and the microtubules of the cytoskeleton 54. In 
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addition to promoting translocation of GLUT4 from cytosolic retention pools to the 
PM, aPKCs promote fusion of GLUT4-containing vesicles with the PM through 
the phosphorylation of VAMP2 55. This action results in the association of this 
SNARE protein with Munc18c, leading to dissociation of the syntaxin4/Munc18c 
complex and subsequent fusion of the GLUT4 containing vesicles with the PM 56. 
In addition to the aPKC cascade, recent studies suggest that tyrosine 
phosphorylation of Cbl is also important for insulin regulated GLUT4 translocation 
57, 58. In the presence of insulin stimulation Cbl and the adaptor protein Cbl 
associated protein (CAP) are recruited to the insulin receptor kinase by the 
adaptor protein containing PH and SH domains (APS) 59. Once phosphorylated, 
Cbl recruits the adaptor protein CrkII and the guanyl exchange factor protein 
C3G to lipid rafts 60. This clustering of effector and adaptor proteins results in the 
activation of the guanosine triphosphate-binding protein TC10 61. Activated TC10 
has been documented to regulate actin dynamics and phosphoinositides in 3T3-
L1 adipocytes. Actin regulatory targets of TC10 include neural Wiskott-Aldrich 
syndrome protein (N-WASP) 62, the actin related protein-3 (Arp3) 62, and the 
exocyst protein complex 63. While N-WASP and Arp3 regulate actin 
polymerization 62, the exocyst protein complex is thought to influence 
docking/tethering of the GLUT4 containing vesicles at the PM 63. Unfortunately 
dominant negative TC10 mutant studies in myoblasts and myotubes do not 
induce defects in insulin stimulated GLUT4 translocation 64, making the relevance 
of this exciting actin regulatory pathway somewhat questionable, especially in the 
context of my thesis studies. As detailed above and shown schematically in Fig. 
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1, insulin-stimulated glucose uptake is complex and highly regulated. However, a 
multitude of pathologies have been documented to disrupt this regulation and 
lead to insulin resistance in humans. Among the various resistance inducing 
insults, the largest population of defects are associated with obesity 65, 66. As 
such the following subsection will highlight known and postulated defects in 
insulin regulation that have been associated with obesity and over-nutrition. 
 
B.2. Obesity induced defects in insulin resistance 
 In the context of modern lifestyle, with abundant nutrient supply and 
reduced physical activity, it is of interest if excess FAs could decrease skeletal 
muscle insulin responsiveness. In human subjects insulin resistance is highly 
associated with obesity 65, 66, increased circulation of FAs, and accumulation of 
lipids in muscle and fat cells 67, 68. Given that the etiologies of obesity-associated 
insulin resistance are complex and likely involve an imperfectly understood 
interplay of many factors, several well supported mechanisms have been 
described as the basis of fatty acid-mediated regulation of insulin sensitivity 69. 
 Numerous groups in the field have put forth the hypothesis that fatty acids 
and their metabolites are directly responsible for the insulin resistant state. The 
first mention of FAs in the context of glucose metabolism defects was made by 
Randel et. al. This hypothesis suggested that FAs competed with glucose for the 
same oxidative pathway, thus causing impaired glucose metabolism 70. Although 
this early hypothesis was promising, recent 13C and 31P NMR spectroscopy 
analysis of insulin resistant subjects has suggested that it is glucose uptake 71 
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and muscle glycogen synthesis 72, rather than glucose catabolism that is 
impaired 73. Further supporting a role for defects in glucose uptake, it was shown 
that lipid infusion impaired tyrosine phosphorylation of IRS and was associated 
with activation of PKCθ. Additionally, this Ser/Thr kinase is known to be 
expressed at greater levels in high fat fed rats 74. From these observations, 
Shulman and colleagues have suggested that serine phosphorylation of IRS is 
the primary mechanism for FA-induced insulin resistance. In this model FAs and 
their metabolic intermediates (i.e. acyl-Co enzyme As [CoA]s, ceramides, and 
diacylglycerides (DAGs)) act as signaling molecules. In conditions that elevate 
these signaling lipids kinases such as PKCθ, Jun kinase (JNK), and the inhibitor 
of nuclear factor-κB (NF- κB) kinase-β (IKKβ) are activated and can 
phosphorylate serine residues of IRS, thus causing defects in the tyrosine 
phosphorylation of IRS and impeding canonical insulin signaling 71, 75.  
Based on the observation that saturated FAs clearly decrease insulin 
sensitivity, while unsaturated FAs exert a weaker effect 76; an alternative, yet 
related, hypothesis for FA-induced insulin signaling defects has been suggested 
by Summers and colleagues. This work was bolstered by the observations that 
palmitate, the most prevalent saturated FA in circulation and muscle 77, 
stimulates de novo synthesis of ceramide. This common sphingolipid 
dramatically inhibits insulin signaling at the level of Akt phosphorylation 10, 13, 78. 
Additionally, ceramide content is negatively correlated with insulin sensitivity in 
humans 79, and when cultured myotubes and adipocytes are treated with 
ceramide analogues, they display diabetic-like defects in insulin-stimulated 
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glycogen synthesis and glucose uptake 10, 13. Mechanistic studies in cultured 
C2C12 myotubes and human myotubes have revealed that blocking ceramide 
accumulation using fumonisisn B1, cycloserine, or myriosine (inhibitiors of 
ceramide synthesis), prevented the palmitate induced defects in Akt signaling 10, 
80-82. Furthermore, depletion of cellular ceramide pools via overexpression of acid 
ceramidase recapitulates the resistance to palmitate insult 83. The mechanism by 
which ceramides inhibit insulin signaling appears to be multifaceted including 
activation of protein phosphatase 2A (PP2A), inhibition of Akt translocation to the 
PM, and activation of the Ser/Thr kinases JNK and IKK. One of the earliest 
identified targets for ceramide induced insulin resistance was PP2A. This 
phosphatase is known to dephosphorylate Akt, thus blunting the insulin signaling 
and inducing resistance 84, 85. Ceramides have also been suggested to inhibit Akt 
translocation to the PM, preventing its phosphorylation and subsequent 
activation. This inhibition has been attributed to PKCζ-mediated phosphorylation 
of Ser34 on the PH domain of Akt, which acts to prevent binding of Akt with PIP3 
86. Further confirming these findings, the negative effects of ceramide were 
reversed in the presence of PKCζ inhibitors or expression of a dominant negative 
PKC construct 80. A final mechanism by which ceramides may induce insulin 
resistance is through the activation of Ser/Thr kinases JNK and IKK by facilitating 
the inflammatory cytokine tumor necrosis factor alpha (TNFα) 87-89. 
The hypothesis that the inflammatory state associated with obesity may 
induce insulin resistance is not isolated to ceramide associated defects. It has 
long been appreciated that the chronic, systemic inflammation that is associated 
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with obesity-related insulin resistance may in fact have a causal role in its 
development 90-92. This systemic inflammation is characterized by an infiltration of 
the adipose by macrophages (adipose tissue macrophages [ATM]) 93, 94. Thus in 
the expanding fat-mass an activation of the ATMs stimulates the production and 
accumulation of inflammatory cytokines associated with insulin resistance such 
as tumor necrosis factor-alpha (TNFα), C-reactive protein (CRP), and interluekin-
6 (IL-6). The accumulation of these inflammatory molecules is likely to cause the 
activation of JNK seen in skeletal muscle, leading to serine phosphorylation of 
IRS and insulin resistance 71, 75. Additionally, cytokine-mediated insulin resistance 
is also associated with activation of the SOCS proteins 95, 96. These proteins 
induce resistance by decreasing IRS tyrosine phosphorylation or targeting the 
IRS proteins for proteasomal degradation 97, 98. Dysfunctions in mitochondria 
processes and the production of reactive oxygen species (ROS)/oxidative stress 
are also of considerable interest in having a hand in compromising insulin action 
(these specific topics are reviewed in the following references 99, 100). Although it 
is possible that one of these mechanisms dominates, a consensus in the field is 
that these mechanisms are interdependent, and it is likely that their dynamic 
interplay underlies the pathophysiology of insulin resistance 69. 
 Although the mechanisms of regulation and resistance covered in the 
previous two subsections focused primarily on signaling events/defects, a 
growing hypothesis in the field is centered on regulation of GLUT4 translocation 
by PM and cytoskeletal dynamics. As this is also of great interest to our group, 
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and the work described in this text, the following subsection will highlight 
cytoskeletal and PM regulation of GLUT4. 
 
B.3 Cytoskeletal and plasma membrane regulation of GLUT4 
 While the primary mode of cellular glucose transport is regulated by the 
insulin and its signaling pathway, a growing body of literature has established a 
role for cytoskeletal and PM dynamics in the regulation of glucose transport. The 
cortical actin cytoskeleton is a highly dynamic meshwork located immediately 
beneath the PM and shown to play an important role in insulin-stimulated GLUT4 
translocation and glucose transport in skeletal muscle and adipose tissue 62, 101-
105. Furthermore, pharmacological disruption of the cortical actin cytoskeleton 
with latrunculin B 106-108 cytochalasin D 103, or botulinum toxin C2 109 inhibits 
insulin-stimulated GLUT4 translocation, adding additional evidence to the role of 
actin in insulin-stimulated GLUT4 translocation 110. A well documented effect of 
insulin stimulation on the actin cytoskeleton in cultured myotubes and adipocytes 
is membrane ruffling 111, 112. This dynamic reorganization of the actin 
cytoskeleton has been observed as early as 20 seconds after insulin stimulation 
and may regulate vesicle accumulation at these membrane sites 113. A role for 
the regulation of GLUT4 translocation by the actin cytoskeleton is further 
evidenced by the formation of actin comet-tails during insulin-stimulated 
translocation in both adipocytes and muscle cells 107, 114, 115. A possible 
mechanism by which GLUT4 containing vesicles interact with the actin 
cytoskeleton is through the insulin-responsive aminopeptidase (IRAP) protease. 
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This constitutive member of the GLUT4 vesicles 116-118 contains an amino 
terminal domain that may regulate actin comet tails 119 necessary for 
translocation 43, 114. 
 The proximity of the cortical actin cytoskeleton to the PM may be 
important to its regulation as several components of the PM are known to 
regulate its remodeling 102, 111. In vitro analyses suggest that this may be 
mediated through proteins that regulate cytoskeletal architecture including the 
Rho GTPase cdc42 120, the neural Wiskott-Aldrich syndrome protein (N-WASP) 
121, and the actin capping/severing protein gelsolin 110. 
 Recent investigations of hyperinsulinemia-induced insulin resistance have 
identified a therapeutically targetable lipid-based mechanism for impaired GLUT4 
translocation. This mechanism entailed an increase in PM cholesterol that 
weakened cortical filamentous actin (F-actin) structure important for GLUT4 
regulation 122-126. A role of cholesterol in the pathogenesis of cardiovascular 
disease is well recognized and an appreciation for this lipid in other abnormalities 
such as neurodegenerative disorders and glucose intolerance is emerging 127-129. 
In direct support of a regulatory role of cholesterol, decreases in membrane 
fluidity dampen insulin action 130 and pathological increases in membrane 
cholesterol due to disease states impair insulin receptor activation 131. A report 
from Younsi et al. 132 recently found that erythrocyte membranes from insulin-
resistant subjects had significantly higher cholesterol content than erythrocyte 
membranes from insulin-sensitive individuals. It has been shown by several 
groups that hydrolysis of sphingomyelin by sphingomyelinase activates GLUT4 
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translocation and glucose transport 8, 124, 133. Further findings from our group have 
demonstrated that this insulin independent effect on GLUT4 translocation was 
associated with a loss of PM cholesterol 124. Additional observations which have 
confirmed this initial finding involve depletion of membrane cholesterol and 
enhancement of insulin and GLUT4 action by methyl-β-cyclodextrin (βCD), 124 
nystatin, and filipin treatments 124 and more recently with chromium picolinate 
(CrPic) 125, 134. While these findings suggest that excess membrane cholesterol 
may play a role in cellular insulin resistance, the hypothesis that membrane 
cholesterol accrual, and its reciprocal regulation of cortical F-actin, may be 
induced by the diabetic milieu has yet to be determined and as such is a primary 
focus of my work presented in Chapter II A and B. 
 In light of the defects observed in T2D and obesity, intense research is 
focused on those endogenous systems and pharmaceutical therapies that may 
correct or slow the progression of insulin resistance. One of the more promising 
of these therapies, the activation of the 5’-AMP Dependent Protein Kinase 
(AMPK), is the focus of studies described in Chapter II C. As such the 
structure/function, targets, and regulation of insulin response/sensitivity by this 
kinase will be highlighted in the following section and subsections. 
 
C. 5’-AMP Dependent Protein Kinase 
 It is well appreciated that physical exercise positively modulates glucose 
homeostasis in healthy individuals, as well as in individuals with T2D 135. This 
modulation is based on the fact that muscle contraction is a potent stimulus of 
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glucose transport activity 136, 137, as well as an enhancer of insulin sensitivity in 
skeletal muscle 138-140, which is the primary tissue responsible for whole body 
glucose disposal 22. This exciting characteristic of exercise, in the context of 
insulin resistance, may be central to explain the phenomenon that regular 
exercise can prevent or delay the onset of T2D 141, 142. Although the exact 
mechanism/signal that elicits the glucose response has yet to be elucidated, 
several effectors such as; calcium 143, 144, nitric oxide (NO) 145, 146, bradykinin 147 
and AMPK 148, 149 have also been implicated in contraction/exercise-stimulated 
glucose transport. Among these possible mechanisms, a central, though not 
exclusive, role for the energy sensing kinase AMPK has been established. In 
addition to being activated during contraction/exercise, AMPK has also been 
proposed as the mediator of multiple antidiabetic therapies such as; metformin 
150, 151, the plant sterol β-sitosterol 152, polyphenolic compounds such as 
resveratrol 153-156 and epigallocatechin gallate  157, 158, berberine 159, and bitter 
melon 160. Furthermore, AMPK has been identified as a nexus for endogenous 
insulin-sensitizing adipokines and cytokines such as adiponectin 161, 162, leptin 162-
164, and IL6 165-167. Together these findings establish AMPK as a candidate of 
great interest for insulin resistance and T2D therapy. 
 
C.1. AMPK Structure and Regulation 
 Often referred to as a “fuel gauge” for cellular energy regulation; AMPK 
functions to maintain cellular energy homeostasis 168, 169. This heterotrimeric 
Ser/Thr protein kinase is found in a multitude of tissues 170 and is conserved from 
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yeast to human 171. The kinase is composed of three subunits the catalytic α, and 
regulatory β and γ 172. There are two isoforms of the α subunit. α1 containing 
complexes are ubiquitously expressed and α2 containing complexes, which are 
more highly expressed in the heart, liver, and skeletal muscle 173, 174. Cellular 
location and target specificity of the two isoforms is varied 175, 176, hinting that 
these isoforms may have different roles in maintaining cellular homeostasis. In 
addition to stabilizing the kinase complex, the β and γ subunits also contribute 
regulatory roles to the kinase activity. Specifically, the β subunit has been shown 
to contain a glycogen binding domain, and more importantly this domain is 
associated with inhibition of the kinase when glycogen is bound 177, 178. 
Furthermore, the γ subunit contains multiple cytsathionine-β-synthase binding 
domains (CBS), important for the binding of adenosine containing molecules 179, 
and specifically 5’-adenosine monophosphate (AMP) which activates the kinase 
in an allosteric manner 180. 
 Many of the activators of AMPK in skeletal muscle are cellular stressors 
that lead to the depletion of high-energy molecules such as 5’-adenosine 
triphosphate (ATP), phosphocreatine, and glycogen. This leads to the 
accumulation of AMP, which binds to the CBS domain of the γ subunit 180 and 
leads to a subtle increase in kinase activity. In addition to the allosteric activation, 
this binding causes a conformational change that makes the α subunit a more 
favorable target for its upstream kinases on Thr172 of the activation loop 181-183. 
Recent work has elucidated two potential kinases for residue Thr172 of AMPKα, 
LKB1 184-186 and the β isoform of calmodulin-dependent protein kinase kinase 
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(CaMKK-β) 187, 188. This phosphorylation has been documented to be essential 
182, 189, 190 and highly associated with the level of kinase activity 190. 
 
C.2. AMPK Targets 
 Once activated AMPK induces metabolic changes both acutely, due to 
direct regulation through phosphorylation of targets, and chronically, through 
regulation of gene expression 191-193, to restore intracellular energy homeostasis. 
Many of these metabolic responses are similar to the adaptive processes 
induced by endurance training such as increased uptake and metabolism, 
especially oxidation, of glucose and fatty acids. Additionally, AMPK activation has 
been documented to regulate the accumulation of those enzymes central to the 
catabolism of these energy sources, including those of the mitochondria 191-197. 
Acutely, AMPK activation functions to restore energy homeostasis by inhibiting 
energy consuming (anabolic) pathways, while stimulating catabolic pathways 
which increase cellular energy status (specifically ATP) 168, 169. Well documented 
targets include phosphorylation of acetyl-CoA carboxylase (ACC) on Ser79 and 3-
hydroxy-3-methylglutaryl CoA reductase (HMGR) on Ser872. The phosphorylation 
of ACC stimulates a switch from synthesis to oxidation in fatty acid metabolism 
via inhibition of the activity of this enzyme. This phosphorylation-mediated 
inhibiton results in a decreased level of its product, malonyl-CoA 198-200. 
Additionally, AMPK has been shown to activate malonyl-CoA decarboxylase, 
further depleting malonyl-CoA levels 201. The decrease in this key intermediate of 
FA synthesis relieves the inhibition of carnitine palmitoyltransferase I (CPT-1), 
21 
allowing for increased transport of fatty acids into the mitochondria for oxidation 
202-204 while concomitantly decreasing substrate for fatty acid esterification. 
Similarly AMPK directly phosphorylates and inhibits HMGR resulting in 
decreased lipid biosynthesis, and specifically that of cholesterol 205-207. As this 
interaction is of key importance to my thesis work, this regulation will be detailed 
in a subsequent section of this chapter. 
 
C.3. AMPK Regulation of Glucose Transport 
 As previously mentioned, AMPK activation has been documented to 
positively regulate transcription of genes essential for glucose transport/oxidation 
such as: GLUT4 192, 208-210, citrate synthase, succinate dehydrogenase, 
cytochrome C 194, and Peroxisome proliferator-activated receptor gamma, 
coactivator 1 alpha (PGC-1α) 211-213. The increased expression of GLUT4 has 
been mechanistically traced to activation of the key transcription factors myocyte 
enhancer factor-2 (MEF-2), GLUT4 enhancer factor (GEF) 214, and nuclear 
respiratory factor 1 (NRF1) 193, 215. In addition to expanding the long-term 
capacity for glucose transport/oxidation, AMPK activation has also been 
documented to increase glucose transport acutely in skeletal muscle 216 209, 217 
and cultured myotubes such as: L6 218-220, C2C12 221, and H-2Kb 222, 223. 
Furthermore this transport has been shown to be mediated by GLUT4 
accumulation at the PM 224. In addition to the insulin-mimetic actions of AMPK, 
activation of this kinase is also known to increase insulin sensitivity/response 225-
227. While the precise mechanism(s) for both the insulin-mimetic and insulin-
22 
sensitizing actions of AMPK are not well understood, several hypotheses have 
been put forward. Most well received among these possible explanations is the 
phosphorylation of AS160/TBC1D4 or its homolog TBC1D1 by AMPK. This distal 
member of the canonical insulin signaling pathway is phosphorylated in response 
to both insulin and AMPK activation 228-230, and has been directly tied to 
regulation of GLUT4 trafficking. Furthermore, mutation of the punitive 
phosphorylation residues on this Rab-GAP prevents AMPK-mediated 
accumulation of GLUT4 at the PM 231. Alternatively, the role of AMPK as a 
regulator of cellular cholesterol homeostasis, as well as previous work from our 
group highlighting a role for PM cholesterol in the regulation of GLUT4 trafficking, 
may suggest that at least a portion of the AMPK-mediated accumulation of 
GLUT4 at the PM is regulated in a PM cholesterol-dependent manner and as 
such is a primary focus of my work presented in Chapter IIC. 
 With the hypothesis that AMPK may be regulating the cellular cholesterol 
distribution, it is important to understand the normal production, trafficking, and 
efflux of this essential membrane component. The following section and 
subsections will outline cellular cholesterol homeostasis in the context of its 
synthesis, efflux, and defects that occur in states of insulin resistance. 
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Fig. 1 Insulin mediated regulation of glucose transport in skeletal muscle. 
Schematic of several cellular components necessary for regulated GLUT4 
trafficking in response to insulin or AMPK stimulation. These events lead to the 
insertion of GLUT4 transporters into the PM and subsequent glucose transport. 
Detailed discussion of each component shown above can be found in the 
previous sections. 
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D. Intracellular Cholesterol Homeostasis 
 Cellular membranes are comprised of cholesterol and phospholipids, at a 
ratio slightly less than 1:1 232. Both lipid types are essential for the regulation of 
both membrane structure and function 233, 234. Cholesterol organization within 
membranes has been documented to be complex and dependent upon the 
composition of the membrane as well as the concentration of cholesterol 235, 236. 
Furthermore, it has been demonstrated that cholesterol displays preferential 
interaction with specific membrane lipids and proteins to form microdomains 237, 
238 termed lipid rafts. These rafts have been documented to be essential to cell 
function, influencing signaling, adhesion, and motility 239. This differential 
distribution is not restricted within the PM but is also found between membranes 
of the cell. The vast majority of cellular cholesterol, 65-90%, is found in the PM 
232 where it constitutes 35-45% of all PM lipids 240. Cholesterol is also distributed 
in membranes of the endocytic pathway and endoplasmic reticulum (ER), (10 
and 0.5% of total cholesterol, respectively) 241-244. Although extracellular 
cholesterol is delivered via low density lipoprotein (LDL), it can be synthesized de 
novo by all nucleated cells. This synthesis utilizes acetyl CoA through a pathway 
involving the conversion of mevalonate to lanosterol, which is then further 
modified by several enzymes to form cholesterol 245.  
 
D.1 Regulation of Cholesterol Synthesis and Efflux 
While it is an essential membrane lipid, cholesterol can also be extremely 
detrimental to cellular function. Because cells accumulate cholesterol from both 
internal (synthesis) and external (LDL) sources, the overall balance must be 
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tightly regulated. As such, mammalian cells have developed an exquisite 
regulatory system for the regulation of cholesterol. This regulation is primarily 
achieved through feedback control of HMGR protein levels, the rate-limiting 
enzyme of cholesterol synthesis 246. The regulation of HMGR protein levels are 
maintained through the actions of specific membrane bound proteins of the ER 
including; the sterol response element binding protein (SREBP), SREBP 
cleavage-activating protein (SCAP), and insulin-induced protein (INSIG) 1&2 247. 
A schematic representation of this important system is shown in Fig 2. As only a 
small portion of the total cellular cholesterol (0.5%) is contained in the ER 
membrane 243, 244, and therefore in contact with the major regulatory mechanism, 
constant and rapid exchange with the PM is necessary to monitor the largest 
pool of cellular cholesterol 248, 249. This trafficking ensures that rather subtle 
changes in PM cholesterol levels stimulate rapid 244 changes in ER cholesterol 
regulatory proteins. Specifically, in the presence of sufficient sterol levels (>5% of 
total ER lipids) 250, HMGR and SCAP both bind to INSIG. Once bound to the 
INSIG protein HMGR is ubiquitinated and degraded, while SCAP and the bound 
SREBP are retained in the ER 251, 252. As SREBPs are transcription factors that 
activate transcription of all required cholesterogenic genes 253, 254, sequestration 
of these proteins prevents further sterol synthesis and maintains appropriate 
membrane structure/function. When sterol levels drop below 5% of total ER 
lipids, HMGR and SCAP no longer bind INSIGs 250. This release from INSIG 
prevents the degradation of HMGR while facilitating the trafficking of 
SCAP/SREBP from the ER to the Golgi complex via coat protein complex (COP) 
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II coated vesicles 255, 256. Once in the Golgi apparatus, SREPBs are 
proteolytically cleaved from the immature 125 kD form to produce the mature and 
active 68 kD transcription factor that translocates to the nucleus 247. This 
proteolytic processing is mediated by Site-1 257, 258 and Site-2 proteases 259, two 
Golgi-resident, membrane-bound proteases. The mature SREBPs bind to the 
sterol response element (SRE) and activate transcription of all necessary genes 
for sterol synthesis 253, 254, including up to a 200-fold increase in HMGR 260, 261.  
Several different isoforms of SREBPs (SREBP-1a, -1c, and 2) are 
expressed in mammals and each regulates a slightly different set of lipogenic 
genes 262. SREBP-1c is encoded from the SREBP-1 gene that also encodes an 
almost identical protein designated SREBP-1a 262. Interestingly, expression of 
SREBP-1 is enhanced by insulin in liver, fat, and skeletal muscle 263-266. Similarly, 
levels of SREBP-1 are increased in the presence of hyperinsulinemia 267-269. 
SREBP-1 plays an active role in regulating the transcription of genes involved in 
fatty acid synthesis and, albeit to a lesser extent, those involved in cholesterol 
synthesis 253. The other SREBP isoform (SREBP-2), is relatively specific to 
cholesterol synthesis, is derived from a different gene and expression of this 
isoform is controlled by cellular sterol concentration 270. 
In addition to the regulation of cholesterol via expression, enzyme activity 
levels can be modulated by phosphorylation 271. It has long been documented 
that HMGR activity is increased in the presence of insulin and repressed by 
glucagon treatment 271. Interestingly, the antidiabetic AMPK (described 
previously) has been shown to phosphorylate and regulate HMGR in response to 
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decreased cellular energy status 272, 273. Furthermore HMGR is regulated by the 
cholesterol synthetic pathway. In a classic example of feedback inhibition, 
lanosterol, a downstream intermediate of cholesterol synthesis, can stimulate 
proteasomal degradation of HMGR 274. 
In addition to HMGR regulation, cholesterol levels are decreased through 
increased Acyl-coenzyme A:cholesterol acyltransferase (ACAT) mediated 
esterification and storage 275 or trafficking events such as ATP-binding cassette 
transport proteins (ABCA1 & ABCG1) mediated efflux 276, 277. The efflux of 
cellular cholesterol is facilitated by the actions of the nuclear factor, liver X 
receptor (LXR), which binds in heterodimers with the retinoic-X-receptor 
(RXR278). Activation of LXR is mediated by the binding of this nuclear factor with 
its ligands. Though not completely elucidated, the likely endogenous ligands for 
LXR are oxysterols. Several candidates have been suggested including 
intermediates from steroid hormone synthesis or from cholesterol synthesis shunt 
pathways such as 27-hydroxycholesterol 279 or 24,25-epoxycholesterol 280, 
respectively. Upon the binding of ligand to LXR, the nuclear factor is able to bind 
target promoters such as ABCA1 281, inducing gene transcription and increasing 
cellular cholesterol efflux. 
As detailed above, the regulation of cholesterol is tightly maintained in 
mammalian cells via production and efflux; however, this homeostatic regulation 
can be disturbed. The following subsection will describe the dysregulation of 
cholesterol homeostasis during insulin resistance  
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D.2 Dysregulation during Insulin Resistance 
 The extremely sensitive systems of regulation described in the previous 
section ensure that cellular cholesterol levels are constantly monitored, and 
presumably held in check. However, disease states are often characterized by a 
disruption of cellular homeostasis. Specifically, insulin resistance and the 
metabolic syndrome-X are closely associated with dyslipidemia including 
elevated LDL and decreased high density lipoprotein (HDL) levels, suggesting a 
dysrugulation in cholesterol homeostasis driven by the insulin resistant state 282. 
As previously mentioned, it is of interest to note that expression of SREBP-1 is 
enhanced by insulin in skeletal muscle, liver, and fat 263-266. Additionally, SREBP 
activity has been documented to be increased in the presence of 
hyperinsulinemia 267-269 with a prediction being that the machinery of cholesterol 
synthesis would be elevated. Further exacerbating the insulin-driven 
accumulation of cholesterol, the activity of HMGR is itself enhanced in the 
presence of insulin 271. Observations from our group suggest that 
hyperinsulinemia is associated with elevated PM cholesterol and insulin 
resistance in 3T3-L1 adipocytes that can be rescued by cholesterol removal. 
Excitingly, removal of cholesterol from the PM is associated with GLUT4 
accumulation and increased insulin-stimulated glucose uptake 11, 124, 125, further 
confirming a role for PM cholesterol in insulin and GLUT4 action. An interesting 
postulate is whether other forms of insulin resistance (i.e. excess FAs) are 
marked by increased PM cholesterol and as such is a primary focus of my work 
presented in Chapter IIA. 
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Fig. 2 Regulation of cellular cholesterol accrual. Shown above is a schematic 
of several cellular components necessary for the regulation of cholesterol 
homeostasis. The largest pool of cellular cholesterol is found in the PM at ~ 1:1 
ratio with phospholipids (A.). Under normal to elevated concentrations of 
cholesterol Scap and SREBP are bound to INSIG and retained in the ER (B.). In 
conditions of decreased cellular cholesterol Scap and SREBP are released from 
INSIG and translocate to the Golgi complex (C.). In the Golgi complex SREBP is 
cleaved from the “immature” 125 kD form to the mature transcription factor of 68 
kD (D.). This 68 kD fragment translocates to the nucleus where it binds to 
promoter regions containing SRE (i.e., HMGR [E.]). Cells may also accumulate 
cholesterol via LDL-mediated cholesterol transport (F.). Detailed discussion of 
each component shown above can be found in the previous sections. 
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 The accumulation of PM cholesterol during states of insulin resistance is 
of great interest to our group. However, an often asked addendum to this 
postulate involves the mechanism responsible for the production of the 
cholesterol (i.e. where does the cholesterol come from?). A possibility that we 
favor involves nutrient-mediated excess glucose flux through the hexosamine 
biosynthesis pathway (HBP), resulting in transcriptional reprogramming of the 
cell for a more cholesterogenic phenotype. With this hypothesis in mind the 
following section and subsections will detail the HBP, its regulation, and 
dysregulation in states of insulin resistance. 
 
E. The Hexosamine Biosynthetic Pathway 
 In the context of modern lifestyle, with abundant nutrients and reduced 
physical activity, it is of interest whether excess nutrients are acting directly to 
decrease skeletal muscle, as well as whole body, insulin responsiveness. Given 
that the etiologies of obesity-associated insulin resistance are complex and likely 
involve an imperfectly understood interplay of many factors, the concept of 
“chronic over-nutrition” is an attractive and integrative explanation for the global 
abnormalities in organs and pathways that are associated with T2D and insulin 
resistance. The mechanistic basis of nutrient sensing is not well known and is 
likely to be both complex and redundant. However, concerted effort has been 
made to identify fuel sensing pathways that control the distribution of nutrients for 
long term storage. The flux of HBP is known to parallel substrate (glucose) 
availability and thus can be considered a nutrient sensor 283, 284. Further 
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solidifying its importance in human pathophysiology, the HBP has been 
implicated in the development and progression of insulin resistance. With this in 
mind, the HBP becomes a candidate of great interest. 
 
E.1. Regulation of the HBP 
Under normal nutrient load, 2-5% of glucose taken into the cell is shunted 
from the glycolytic pathway and into to HBP 285-287 through glutamine:fructose-6-
phosphate amidotransferase (GFAT), the rate limiting enzyme of this pathway. 
These molecules are ultimately converted to uridine diphosphate-N-
acetylglucosamine (UDP-GlcNAc), before transfer of single GlcNAc moieties to 
hydroxyl groups on Ser/Thr residues of target proteins by O-linked N-
acetylglucosamine transferase (OGT)288. The reverse reaction, removal of the O-
GlcNAc moiety, is catalyzed by the O-GlcNAcase (OGA) enzyme289, 290. Thus the 
cycling of this post translational modification is rapid, transient, and suitable for 
signaling. O-GlcNAc is common in cytoplasmic and nuclear proteins and has 
been implicated in multiple cellular processes including transcriptional regulation, 
signal transduction, and metabolism 291, 292. Interestingly, OGT is primarily found 
in the nucleus, while OGA is localized in the cytoplasm. However a considerable 
fraction of OGA (~20%) is found in the nucleus and a reciprocal portion of OGT is 
located in the cytoplasm 290. Furthermore, OGT and OGA are often found in the 
same complexes, suggesting coordinated regulation of these opposing enzymes 
293. 
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 Although our current knowledge of pathway regulation is somewhat 
superficial; it is known that UDP-GlcNAc is a potent inhibitor of GFAT, 
establishing a potential feedback mechanism of regulation. Unfortunately this 
inhibition is somewhat difficult to understand considering UDP-GlcNAc 
concentrations can rise to millimolar levels in the cell. It is also of interest that 
OGT activity is sensitive to UDP-GlcNAc concentrations and increases as the 
concentration of substrate increases 294. Recent in vivo and in vitro study has 
shown that OGT is phosphorylated and activated by Calmodulin-dependent 
protein kinase IV (CaMKIV) 295. This activation is associated with regulation of 
transcription, signaling, protein localization, and cytoskeletal reorganization 288, 
292. Unfortunately, at this time, little is known about the regulation of OGA activity 
in response to common cellular stimuli. 
 
E.2. Dysregulation of HBP flux and Insulin Resistance 
The HBP is an example of a normal evolutionary adaptation, however, 
chronic and excessive flux through this pathway has been documented to induce 
a diabetic-like phenotype. The detrimental effect of excess flux through this 
pathway was first described by Marshall et al. when they documented the 
induction of insulin resistance to glucose transport in cultured adipocytes 
exposed to hyperglycemia 286. Additional studies suggest this resistance is due to 
defects in GLUT4 translocation and subsequent glucose transport 296, 297. These 
effects were also induced by glucosamine, an intermediate of the pathway. 
Further implicating this mechanism, glucosamine-induced defects were not 
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additive to those induced by hyperglycemia suggesting a shared pathway 298. In 
confirmation of these findings, our group has documented HBP-mediated insulin 
resistance induced by hyperinsulinemia 299, likely to increase glucose flux even in 
euglycemic conditions. This observation may be especially important in light of 
the compensatory hyperinsulinemia observed in pre-diabetes. 
In addition to acting as a sensor of carbohydrate supply, it is likely that 
HBP flux is also influenced by excess lipid load 285. In addition to these in vitro 
studies, several in vivo studies have shown that increased HBP flux through 
overexpression of GFAT resulted in the development of insulin resistance 283, 300, 
301. Furthermore, the resistance inducing capacity of this pathway was 
established when it was found that even a subtle (20%) overexpression was 
sufficient to induce resistance 302. Similarly, inhibition of OGA induces an 
increase in O-GlcNAc levels that is associated with and induction of insulin 
resistance 303. Conversely, overexpression of OGA in diabetic hearts improved 
calcium cycling, an index of resistance that is induced by OGT overexpression 
304. 
 While elevated levels of O-GlcNAc are associated with insulin resistance 
in multiple cell types 302, 303, the exact link between excess HBP flux and insulin 
resistance is not well understood. As such, several mechanisms have been put 
forth to describe this cellular phenomenon. Recent study by the Evans group 
suggests OGT is targeted to the PM by phosphoinositides, where it increases O-
GlcNAcylation and inhibition of key insulin-signaling proteins 305. Alternatively, the 
observation that increases in global phosphorylation are associated with global 
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decreases in O-GlcNAcylation, and vice versa, has lead to the “ying yang” 
hypothesis. This postulate states that O-GlcNAcylation may be competitive to 
phosphorylation on many Ser/Thr residues important for cellular signaling events 
306. Additionally, work from our group has put forth the hypothesis that increased 
O-GlcNAcylation of key transcription factors induces PM and cytoskeletal defects 
leading to an insulin-resistant state 299. The details of this work are the primary 
focus of my work presented in Chapter IIB. 
 
F. Thesis Hypothesis and Specific Aims 
On the basis of these fundamental findings in the field, and the gaps in 
knowledge that I observed, I formulated the following hypothesis for my thesis 
work. Saturated Fatty Acids induce insulin resistance through defects in 
membrane and cytoskeletal dynamics; specifically, elevated PM cholesterol and 
decreased cortical actin polymerization. Conversely, activation of AMPK 
increases insulin sensitivity and GLUT4 action via a lowering of PM cholesterol. 
To test this hypothesis, I constructed the following specific aims: 1) To determine 
the effects of excess FFAs on membrane and cytoskeletal aspects of insulin-
resistance; and 2) to test if changes in PM cholesterol contribute to AMPK-
mediated improvements in insulin and GLUT4 action. 
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Chapter II 
 
Results 
 
II. A.  
Fatty Acid-Induced Plasma Membrane Cholesterol Accrual and Glucose 
Transport Dysfunction 
 
Summary 
 Study has shown that PM cholesterol and cortical F-actin influence the 
regulation of the insulin-responsive glucose transporter GLUT4. As exposure to 
excess FAs induce glucose intolerance by mechanisms imperfectly understood, 
we tested here if PM cholesterol accrual could contribute to the pathogenesis of 
FA-induced defects in skeletal muscle glucose transport. Skeletal muscle from 
high-fat fed animals and insulin-sensitive and insulin-resistant human subjects 
were evaluated. Study also utilized L6 myotubes stably expressing GLUT4 that 
carries an exofacial myc-epitope tag (L6-GLUT4myc) to directly determine the 
impact of excess FAs on the status of membrane cholesterol, F-actin, and 
GLUT4 regulation. High-fat fed, insulin-resistant animals displayed an elevated 
level of skeletal muscle membrane cholesterol and a loss in cortical F-actin, 
compared to normal-chow fed animals. Consistent with a cholesterol component 
of glucose intolerance, human skeletal muscle biopsies revealed an inverse 
correlation between membrane cholesterol and whole-body glucose disposal. 
Mechanistically, exposure of L6-GLUT4myc
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palmitate induced a 27% increase in PM cholesterol that destabilized F-actin and 
decreased insulin-stimulated PM GLUT4 and glucose transport. Cholesterol 
normalization protected against the palmitate-induced defects, whereas 
characteristically measured defects in insulin signaling were not corrected. 
Conversely, experimental loading of L6-GLUT4myc-myotube membranes with 
exogenous cholesterol provoked a palmitate-like cytoskeletal/GLUT4 
derangement, without inducing signaling defects. Our results show that palmitate 
promotes PM cholesterol accrual with cytoskeletal defects that compromise 
GLUT4 function, which can be reversed with cholesterol lowering strategies. 
Moreover, this potentially targetable membrane/cytoskeletal defect is present in 
skeletal muscle from high-fat fed animal models and glucose-intolerant humans. 
 
Results 
 
Muscle membrane cholesterol is elevated in glucose-intolerant animals and 
humans  
 To examine the effect of high-fat diet on muscle membrane cholesterol 
content we obtained muscle biopsies from normal chow and high-fat fed 
C57BL/6J mice and Ossabaw swine. High-fat feeding of C57BL/6J mice for 4 
weeks, which is known to induce glucose intolerance 307-309, induced an increase 
in membrane cholesterol compared to controls (Fig. 3a). This membrane 
cholesterol accrual was also witnessed in high-fat fed Ossabaw swine (Fig. 3b). 
37 
 
Fig. 3 Insulin-resistant human subjects and animal models display skeletal 
muscle membrane cholesterol accrual. Skeletal muscle membrane cholesterol 
from control and high-fat (HF) fed C57/B6 mice (a) and Ossabaw swine (b). 
HOMA values in the Ossabaw swine (c). Plot of glucose disposal rate (GDR) and 
skeletal membrane cholesterol from human subjects with a range of insulin 
sensitivities assessed by hyperinsulinemic, euglycemic clamp (d). Values are 
means ±SE from 3 mice and 6-8 swine per experimental group. *P<0.05 vs. 
control group 
.
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HOMA values shown in Fig. 3c confirm the insulin-resistant phenotype of this 
Ossabaw swine model 310, 311. We also obtained human muscle biopsies from 
individuals across a range of insulin sensitivities. As shown in Fig. 3d, there was 
an inverse correlation between membrane cholesterol content and glucose 
disposal rate. 
 
Palmitate induces glucose transport system dysregulation in muscle cells 
 Exposure of L6-GLUT4myc myotubes to increasing concentrations of 
palmitate (C16:0, a saturated FA documented to be a prevalent lipid in rat muscle 
77 and to desensitize muscle and cultured myotubes to the metabolic effects of 
insulin 13, 312) resulted in a dose-dependent impairment in insulin-stimulated 
GLUT4myc translocation (Fig. 4a). Recapitulating findings of others the 
palmitate-induced defect was significant at 300 µM, a concentration in the upper 
range of human physiology 313, 314. Whereas higher concentrations of this lipid 
were associated with a trend for a dose-dependent increase in basal GLUT4 
translocation and glucose transport (Fig. 4b), this was not the case with the 
physiological concentration of palmitate (Fig. 4c). All subsequent evaluations of 
insulin action and membrane/cytoskeletal features used 300 µM palmitate. 
Consistent with the negative effect of palmitate on insulin-regulated GLUT4 
translocation, insulin-stimulated 2-deoxyglucose (2-DG) transport was impaired 
36% (Fig. 4d). 
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Fig. 4 Palmitate induces insulin resistance in L6-GLUT4myc myotubes. 
Incubation of L6-GLUT4myc myotubes in the presence of palmitate (C16:0) for 
16 hr impairs insulin-stimulated GLUT4 translocation (a & c), induces a basal, 
dose-dependent increase in GLUT4 (b), and 2-deoxyglucose (2DG) uptake (d). 
Open bars, basal; closed bars, 20 min insulin stimulated. Values are means ±SE 
of GLUT4myc/nucleus quantification (a & b) and 2-DG uptake (c). *P<0.05 vs. 
control group, #P<0.05 vs. control insulin group. Values are means ±SE of 
GLUT4myc/nucleus quantification. *P<0.05 vs. control group. 
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Palmitate-induced insulin-resistant myotubes display increased membrane 
cholesterol  
 The preceding data suggested that excess FAs may contribute to PM 
cholesterol accrual. To test this hypothesis, we prepared PM from control- and 
palmitate-treated myotubes. Analogous to the animal and human findings, the 
membranes prepared from the palmitate-induced insulin-resistant myotubes 
displayed a 27% increase in cholesterol compared to control (Fig. 5a, bar 1). We 
next tested if methyl-β-cyclodextrin (βCD)-mediated cholesterol removal of this 
excess cholesterol mitigated the palmitate-induced insulin resistance. A low-dose 
(1 mM) βCD-treatment decreased membrane cholesterol in palmitate-treated 
myotubes to levels witnessed in control (Fig. 5a, bar 2). Strikingly, the 26% 
decrease in insulin-stimulated PM GLUT4 induced by palmitate was completely 
mitigated by the normalization of PM cholesterol content by βCD (Fig. 5c, 
compare bars 1 and 2). βCD treatment of control cells tended to increase basal 
and insulin-stimulated PM GLUT4, yet this did not reach statistical significance 
(Figs. 5b and 5c, bar 3), consistent with observations showing a small, if any, 
effect of 1 mM βCD on basal and insulin-stimulated PM GLUT4 124, 125. It is 
important to note, however, that in the presence of palmitate, the βCD treatment 
increased basal PM GLUT4 (Fig. 5b, bar 2). The basis for this gain is unclear, yet 
likely explains the correction in insulin-stimulated PM GLUT4 content shown in 
Fig. 5c (bar 2). Regardless of the precise mechanism(s), these data show that 
normalizing PM cholesterol during palmitate exposure favorably affects PM 
GLUT4 content and, in turn, permits an insulin-stimulated glucose transport 
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Fig. 5 Cholesterol lowering protects against palmitate-induced insulin 
resistance. Membrane cholesterol (a) GLUT4myc (b & c) and 2-DG uptake (d) 
from control and palmitate-treated L6-GLUT4myc myotubes co-treated without or 
with βCD. Values are means ±SE of membrane cholesterol (a) 
GLUT4myc/nucleus quantification (b & c) and 2-DG uptake (d). Open bars, 
basal; closed bars, 20 min insulin stimulated. *P<0.05 vs. control basal group, 
#P<0.05 vs. control insulin group. 
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response similar to that witnessed in control cells (Fig. 5d, compare bars 1 and 
4). 
 
Defective signal transduction appears independent of PM cholesterol 
accrual 
 Myotubes treated with 100 nM insulin for 5 min displayed an 
approximately 3-fold increase in Akt-2 phosphorylation at serine 474 (Fig. 6, 
lanes/bars 1 and 2). As is well-documented 13, palmitate treatment caused a 
decrease in phosphorylation of Akt-2 (Fig. 6, lanes/bars 3 and 4), the isoform 
primarily responsible for insulin-stimulated glucose transport 40. Strikingly, the 
positive effect of βCD on GLUT4 translocation was not associated with a rescue 
of the palmitate-induced defect in Akt-2 phosphorylation (Fig. 6, lanes/bars 5 and 
6). 
 
Exogenously added cholesterol promotes F-actin loss and GLUT4 
dysregulation 
 To confirm the negative impact of excess membrane cholesterol on 
GLUT4 we used βCD to load exogenous cholesterol into the membrane as we 
have previously documented 124. Treatment of control myotubes with βCD 
conjugated to cholesterol markedly increased membrane cholesterol (Fig. 7a). 
This cholesterol loading decreased cortical F-actin (27±.072%, p = 0.0005) and 
insulin-stimulated PM GLUT4 (Fig. 7b). The loss in insulin responsiveness was 
comparable to that witnessed in the palmitate-treated myotubes. Accordingly, we 
found that palmitate-treated cells displayed a 32% decrease in F-actin (Fig. 8a) 
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Fig. 6 Impaired insulin signaling is not rescued by cholesterol lowering. 
Basal and insulin-stimulated Akt-2 phosphorylation in control and palmitate-
treated L6-GLUT4myc myotubes co-treated without or with βCD. Values are 
means ±SE of phospho-Akt-2. Open bars, basal; closed bars, 5 min insulin 
stimulated. *P<0.05 vs. control basal, #P<0.05 vs. control 5’ insulin 
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Fig. 7 Exogenous cholesterol membrane loading induces cellular insulin 
resistance. Membrane cholesterol (a) and GLUT4myc (b) of L6-GLUT4myc 
myotubes treated with or without 5 mM βCD:cholesterol  Values are means ± SE 
of membrane cholesterol(a) and GLUT4myc/nucleus quantification (b). Open 
bars, basal; closed bars, 20 min insulin stimulated. *P<0.05 vs. control basal, 
#P<0.05 vs. control 5’insulin. 
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and that soleus muscle removed from the same mice we used to measure 
membrane cholesterol (see Fig. 3a), revealed the predicted reciprocal change in 
F-actin (Fig. 8b). Consistent with this cytoskeletal disruption resulting from 
excess membrane cholesterol, the βCD-induced rescue of GLUT4 in the 
palmitate-treated myotubes was associated with a gain in F-actin (Fig. 8a). 
46 
 
Fig. 8 Cytoskeletal derangement is induced by palmitate and high-fat diet 
regimens. Cortical F-actin from control and palmitate-treated L6-GLUT4myc 
myotubes co-treated without or with βCD (a) and skeletal muscle from control (C) 
and high-fat fed (HF) C57/B6 mice (b & c). Values are means ± SE of F-
actin/area.*P<0.05 vs. control. 
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II. B. 
 
The Role of the Hexosamine Biosynthetic Pathway in Fat- and 
Hyperinsulinemia-Induced Insulin Resistance 
 
Summary 
Hyperinsulinemia, hyperlipidemia, and hyperglycemia are conditions known to 
induce insulin resistance and accelerate diabetes progression. Recent study 
suggests mechanisms linking increased HBP activity to PM cholesterol- and 
cortical F-actin-associated impairment of glucose transporter GLUT4 regulation. 
These changes in PM and cytoskeletal architecture and insulin sensitivity were 
reminiscent of those observed in the FA-induced model of insulin resistance, and 
as such, a collaborative project was initiated between myself and another 
student, Guru Pattar, to elucidate a possible common mechanism of insulin 
resistance. Here we tested the hypothesis that PM cholesterol accrual results 
from elevated HBP flux induced by physiological hyperinsulinemia, 
hyperlipidemia, hyperglycemia, or experimental manipulations of the HBP. By 
increasing the flux of glucose through the HBP, PM cholesterol content was 
increased in 3T3-L1 adipocytes and similar trends were observed in L6-
GLUT4myc myotubes. This increase in PM cholesterol occurred concomitantly 
with a loss of F-actin and an induction of GLUT4 dysregulation. Nuclear extracts 
revealed an increase in the cholesterogenic transcription factors specificity 
protein 1 (Sp1), SREBP-1, and NFY, with Sp1 showing increased O-linked 
glycosylation. Consistent with this Sp1 modification eliciting a maximal 
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transcriptional activation of SREBP-1, the mRNA and protein expression levels of 
3-hydroxy-3-methylglutaryl CoA reductase and SREBP-1 itself were elevated. 
The cholesterogenic response associated with increased HBP activity was 
completely prevented in cells where O-linked N-acetylglucosamine transferase 
(OGT) expression was suppressed by siRNA-mediated knockdown. 
Concomitantly, these cells were protected against membrane/cytoskeletal 
abnormalities and insulin resistance. These data causally link increased HBP 
activity to PM cholesterol accrual and cortical F-actin loss that compromises the 
efficient regulation of GLUT4 by insulin. Analogous cholesterol-laden PM and 
actin filament loss in skeletal muscle from streptozotocin-induced hyperglycemic 
mice provide in vivo evidence that membrane and cytoskeletal abnormalities may 
be a contributing distal derangement induced by the HBP that impairs insulin and 
GLUT4 action. 
 
Results 
 
Hyperinsulinemia, hyperlipidemia, hyperglycemia, and glucosamine 
increase PM cholesterol 
 Previous study from our group as well as others has shown that 
physiological hyperinsulinemia 11, 315 316 14, 15, 317 and hyperglycemia 14, 315 
treatments result in an insulin resistant phenotype and loss of cortical F-actin. 
Furthermore, pharmacological manipulation of the HBP with glucosamine 
recapitulates this resistant state 15, 315, 318, 319. Confirming a role for the HBP, this 
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resistance was associated with an increase in O-linked glycosylation 315. 
Concomitant with this resistance we found that 3T3-L1 adipocytes cultured in the 
presence of 25 mM glucose or treated with 5 nM insulin or 2 mM glucosamine 
display a 20-30% increase in PM cholesterol (Fig. 9a-c). Furthermore, pilot data 
from L6-GLUT4myc myotubes cultured in the presence of 25 mM glucose or 
treated with 5 nM insulin, likewise display trends for 12 and 20% elevations in 
membrane cholesterol, respectively (Fig. 9d & e). 
  These initial findings were of interest concerning the previous study on 
fat-induced glucose transport dysfunction, as the FA-induced defects were also 
associated with elevated PM cholesterol (Fig. 5a). Further confirming these 
findings, previous study has shown that lipid infusion in rats 320, and direct 
palmitate, high glucose, or glucosamine treatments in myotubes 16, 321, elevates 
glucose flux through the HBP. Interestingly, we found that conditions which 
activate this pathway are associated with a decrease in F-actin in 3T3-L1 
adipocytes 322 and L6-GLUT4myc myotubes 316. In the context of the present 
work, an intriguing question is whether palmitate, like the other diabetogenic 
insults, increases HBP activity and does this promote a cholesterogenic 
response. To probe this idea we measured O-linked glycosylation, an end 
product of the HBP, and found that palmitate-treated myotubes displayed a 
statistically significant increase in O-linked glycosylation, as determined via anti-
RL2 immunofluorescence (Fig. 10). 
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Fig 9. Excess glucose stimulates PM Cholesterol accrual. Plasma membrane 
fractions from hyperglycemia- (a), hyperinsulinemia- (b), and glucosamine-
treated adipocytes (c) as well as hyperglycemia- (d), hyperinsulinemia- (e) 
treated L6-GLUT4myc myotubes, exhibit increased cholesterol content. Values 
are means ± SE of membrane cholesterol. *P<0.05 vs. control 
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Fig. 10 Palmitate induces HBP flux in L6-GLUT4myc myotubes. Anti-RL2-
detected O-linked glycosylation immunofluorescence from control and palmitate-
treated L6-GLUT4myc myotubes. 
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Diabetogenic insults are associated with activation of cholesterogenic 
factors. 
 Nuclear extracts from 3T3-L1 adipocytes challenged with 
hyperinsulinemia, revealed an increase in the cholesterogenic transcription 
factors Sp1, SREBP-1, and NFY (Fig 11a). Of particular interest in adipocytes 
cultured under hyperglycemic conditions, co-IP of Sp1 with RL-2 revealed a trend 
for an increase in O-linked glycosylation (Fig 11b), a modification associated with 
elevated transcriptional activity of this transcription factor 323-325. Consistent with 
this Sp1 modification eliciting a maximal transcriptional activation of SREBP-1 326, 
327, the mRNA expression levels of Hmgr were elevated and there was a trend for 
the elevation of HMGR protein (Fig 11b and c). While we were unable to detect 
the protein levels due to poor antibody banding in this cell type, L6-GLUT4myc 
myotubes treated with palmitate display an increase in the Hmgr transcript (Fig. 
11d). Collectively, these pilot data hint at an interesting cholesterogenic 
mechanism for physiological hyperinsulinemia-, hyperlipidemia-, and 
hyperglycemia-induced defects in GLUT4 regulation. 
 
HBP regulation of the Cholesterogenic Response  
 The previous observations hinted that the accumulation of PM cholesterol, 
and the resulting insulin resistance, was linked to increased flux through the HBP 
and subsequent glycosylation of targets that are deleterious to insulin and 
GLUT4 action. To more clearly elucidate the role of HBP flux in the development 
of PM cholesterol-mediated insulin resistance, we utilized siRNA to knockdown 
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 Fig. 11. Hyperinsulinemia, hyperglycemia, and hyperlipidemia drive 
cholesterogenic transcription activity. Nuclear fractions reveal an increase in 
Sp1, SREBP-1, and NFY in 3T3-L1 adipocytes cultured in hyperinsulinemic 
conditions (a). O-linked glycosylation of Sp1 is elevated in 3T3-L1 adipocytes 
cultured in hyperglycemic conditions and this corresponds to an increase in 
HMGR protein (b). Hyperinsulinemic 3T3-L1 adipocytes (c) and hyperlipidemic 
L6-GLUT4myc myotubes (d) display elevated Hmgr expression. Values are 
means ± SE of fold Hmgr expression from control. *P<0.05 vs. control 
* 
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OGT. L6-GLUT4myc myotubes were transfected with a calcium-phosphate 
based protocol that displayed high transfection efficiency as determined by the 
detection of the fluorescently labeled  siGLO oligos (Fig. 12a). Specific 
oligonucleotides targeted to OGT (#75, 76, & 77) reduced detectable OGT 
protein by 81, 63, and 54%, respectively, as compared to the control cells 
transfected with scramble oligos (Fig. 12b). All subsequent assays utilized oligo # 
s130675 (#75), as it produced the greatest knockdown. This reduction in OGT 
was associated with a trend for the ablation of palmitate induced increase in O-
linked glycosylation (Fig. 12c), confirming the blockade of this pathway by 
knockdown of the transferase. It should be noted that the global repression of O-
linked glycosylation is expected as we are knocking down all enzymatic transfer, 
thus only non-enzymatic glycosylation events should be occurring in these cells. 
Concomitant with the reduction of OGT, we observed a trend for prevention of 
both hyperinsulinemia- and palmitate-stimulated PM cholesterol accrual as 
compared to the control cells transfected with scramble oligos (Fig. 10d). An 
interesting observation is that both of the siOGT control samples displayed a 
slight increase in PM cholesterol over the siScrm controls (Fig. 12d & e). 
However additional replicates will be needed to confirm this trend. Furthermore, 
in cells where OGT was depleted, there was a trend for the rescue of the cortical 
F-actin defect in both hyperinsulinemia and palmitate treated myotubes (Fig. 12f). 
Consistent with an HBP-mediated increase in cholesterol through Hmgr 
induction, there was a trend for the prevention of hyperinsulinemia-induced 
increase in Hmgr in OGT (Fig. 12g, compare bars 2 and 5) 
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Fig. 12. Knockdown of O-Glycosyltransferase (OGT) with siRNA in L6-
GLUT4myc Myotubes. Calcium-phosphate based transfectionof L6-GLUT4myc 
myotubes with siGlo oligos revealed substantial transfection efficiency (a). 
siRNA-mediated knockdown of OGT (b). O-linked GlcNAc of palmitate-treated 
siOGT myotubes (c). PM cholesterol in palmitate- and hyperinsulinemia-treated 
siOGT myotubes (d & e). F-actin (f) and Hmgr expression (g) in palmitate- and 
hyperinsulinemia-treated siOGT myotubes Values are means ± SE. *P<0.05 vs. 
Scramble (Scrm) control. 
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knockdown myotubes. Surprisingly, there was no trend for increased 
transcription in palmitate treated cells, and no change in the absence of OGT 
(Fig. 12g, compare bars 3 and 6). 
 
In vivo hyperglycemia is associated with increased PM Cholesterol and 
cortical F-actin loss 
 As an in vivo confirmation of our cell culture findings, hyperglycemia was 
induced in mice via low dose streptozotocin (STZ)-mediated ablation of β cells. 
Following five-six weeks of hyperglycemia, analogous trends for cholesterol-
laden PM and actin filament loss were observed in skeletal muscle from these 
animals (Fig. 13a & b). These data suggest that membrane and cytoskeletal 
abnormalities may be a contributing distal derangement induced by the HBP. 
Furthermore, these defects may encompass a mechanistic node of impaired 
insulin and GLUT4 action. 
 While still preliminary, these exciting pilot studies may provide a 
mechanistic link between nutrient excess and PM cholesterol-mediated insulin 
resistance, establishing a long sought after common defect for multiple 
diabetogenic insults. Although defects in glucose tolerance and insulin resistance 
were the focus of the two previous sections of this chapter, an equally interesting 
question is whether states of increased insulin sensitivity/glucose transport are 
associated with reduced levels of PM cholesterol. As such, the following section 
will describe study on the antidiabetic AMPK, and its role in the regulation of PM 
cholesterol, as well as insulin and GLUT4 action.
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Fig. 13. Hyperglycemic mice display PM and cytoskeletal defects. Skeletal 
muscle from STZ-treated mice display a reciprocal increase in PM cholesterol (a) 
and decrease in F-actin structure (b). 
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II. C. 
 
Activation of AMPK Enhances Insulin but Not Basal Regulation of GLUT4 
Translocation via Lowering Membrane Cholesterol: Evidence for Divergent 
AMPK GLUT4 Regulatory Mechanisms 
 
Summary 
 The antidiabetic mechanism of AMPK remains imperfectly understood. 
However, unequivocal evidence documents that enhanced basal and insulin-
stimulated translocation of GLUT4 to the PM is a critical step in AMPK action. 
Furthermore, the ability of AMPK to inhibit energy-consuming biosynthetic 
pathways, such as fatty acid and sterol synthesis appears to be an essential 
aspect of decelerating diabetes progression. Here we tested the prediction that 
AMPK stimulation regulates PM cholesterol content, a membrane parameter 
documented to influence GLUT4 trafficking. Activation of AMPK by 5-
aminoimidazole-4-carboxamide-1-beta-D-ribonucleoside (AICAR) or 2,4-
dinitrophenol (DNP) increased basal and insulin-stimulated GLUT4 translocation 
to the PM in L6-GLUT4myc. Key insulin signaling effectors (e.g., insulin receptor, 
insulin receptor substrate 1, Akt-2, AS160) were not engaged, however, both 
agents diminished PM cholesterol by 25% (P<0.05). Interestingly, PM cholesterol 
replenishment abrogated the AMPK effect on insulin, but not basal, regulation of 
GLUT4 translocation. Conversely, AMPK knockdown prevented the 
enhancement of both basal and insulin-stimulated GLUT4 translocation. These 
data suggest that regulation of basal GLUT4 translocation by AMPK is 
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independent of PM cholesterol lowering, yet this AMPK-mediated loss of PM 
cholesterol positively impacts the regulation of GLUT4 translocation by insulin. 
We propose that divergent signals from AMPK regulate basal and insulin-
stimulated GLUT4 translocation. Perhaps PM cholesterol accrual could be an 
important contributor to impaired insulin responsiveness and glucose intolerance 
and ultimately the diabetic condition that pharmaceutical targeting of AMPK may 
effectively prevent. 
 
Results 
 
AMPK activation in L6-GLUT4myc myotubes 
 L6-GLUT4myc myotubes treated with either AICAR or DNP for 45 or 30 
min, respectively, resulted in a characteristic increase in AMPK Thr172 
phosphorylation (Fig. 14a). The phosphorylation of this residue has been shown 
to be associated with activation of the kinase 190. Consistent with AICAR and 
DNP stimulating AMPK Thr172 phosphorylation via an ATP-independent [i.e., 
AICAR conversion to the 5’-AMP analogue 5-aminoimidazole-4-carboxamide 1-
β-D-ribofuranotide (ZMP)] and an ATP-dependent mechanism (i.e., mitochondrial 
uncoupling that prevents cellular production of ATP), Fig. 14b shows that 
intracellular ATP was unchanged by AICAR, yet decreased ~40% following DNP 
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Fig. 14 AMPK activation in L6-GLUT4myc myotubes. Myotubes were left 
untreated or treated with AICAR or DNP, and cell lysates were subjected to 
SDS/PAGE and immunoblot analysis using anti-phospho AMPK (a) and anti-
phospho ACC (c) antibodies. Treatments and procedures, as well as ATP 
determinations (b) were performed as described in Methods. Values are means 
±SE, *P<0.05 vs. control group. 
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treatment. Consistent with the increase in AMPK activity; the phosphorylation of 
ACC Ser79, the most well-characterized phosphorylation target of AMPK, 
increased after AICAR and DNP treatment (Fig. 14c). Use of an antibody that 
recognizes HMGR when phosphorylated on Ser872 also suggested that AICAR- 
and DNP-induced phosphorylation of this target, yet the intensity of the bands 
detected were too faint for accurate analysis. 
 
AMPK signaling enhances basal and insulin-stimulated GLUT4 
translocation 
 AICAR and DNP treatment of the L6-GLUT4myc-GLUT4myc myotubes 
elicited an increase in basal PM GLUT4 (Fig. 15a, compare bars 1, 3, and 5), as 
well as an increase in insulin response at the level of GLUT4 translocation to the 
PM (Fig. 15a, compare bars 2, 4, and 6). As documented by others 328, this 
increase in basal and insulin-stimulated GLUT4 translocation was not associated 
with phosphorylation/activation of key insulin signaling molecules such as the 
insulin receptor substrate 1 and Akt-2 (Fig. 15b). We also did not witness an 
AICAR- or DNP-induced increase in basal or insulin-stimulated phosphorylation 
of AS160 (Fig. 15c). 
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Fig. 15 AMPK activation increases PM GLUT4 independent of insulin 
signaling enhancement. PM GLUT4 from myotubes were treated as described 
in Fig. 12 in the absence (open bars) or presence of insulin (closed bars). Values 
are means ±SE of GLUT4myc/nucleus quantification (a). phospho-IRS-1 and 
phospho-Akt2 (b), and phospho-AS160 (c) levels were determined as described 
in Methods. Values are means ±SE of phospho-AS160 quantification (c)*P<0.05 
vs. basal- treatment group, #P<0.05 vs. basal-control group, †P<0.05 vs. insulin-
control group. 
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AICAR- and DNP-treated L6-GLUT4myc myotubes display a loss in PM 
cholesterol 
 Concomitant to their effects on GLUT4 trafficking, both AICAR and DNP 
elicited a 25% decrease in PM cholesterol (Fig. 16). As we have 
previouslyreported 124, extraction of ~25% of PM cholesterol with a low dose of 
βCD (Fig. 16b) also resulted in a reciprocal increase in basal and insulin-
stimulated PM GLUT4 (Fig. 16c). To further dissect the role of PM cholesterol in 
the AMPK mediated translocation events, L6-GLUT4myc myotubes were treated 
with AICAR and DNP in the presence of exogenous cholesterol conjugated to 
βCD. Fig. 15a shows that this cholesterol addition strategy mitigated the 
enhancement of insulin-stimulated GLUT4 translocation induced by DNP (Fig. 
17a, compare bars 2, 4, 6 and 8). Interestingly, the increase in basal PM GLUT4 
induced by DNP was not prevented (Fig.17a, compare bars 1, 3, 5 and 7). Basal 
and insulin-stimulated GLUT4 translocation in the absence of DNP was not 
affected by the exogenous cholesterol (Fig. 17a, compare bars 1, 2, 5 and 6). 
Similar trends were observed with AICAR as a stimulant (Fig. 17b). 
 
AMPK mediates cholesterol-dependent and -independent regulation of 
GLUT4  
 In contrast to our expectation, the increase in basal PM GLUT4 induced 
by DNP and AICAR was not eliminated by replenishing the PM cholesterol, 
hinting at a potential divergent AMPK-mediated pathway that controls basal PM 
GLUT4 independently of cholesterol. If true, we reasoned that siRNA-mediated 
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 Fig. 16 AMPK activation decreases PM cholesterol PM cholesterol 
from myotubes treated as described in Fig. 12 (a) or with 5 mM βCD (b). PM 
cholesterol content was determined as described in Methods. Values are means 
±SE of PM cholesterol. PM GLUT4 from myotubes were treated with or without 5 
mM βCD in the absence (open bars) or presence of insulin (closed bars). 
*P<0.05 vs. basal- treatment group, #P<0.05 vs. basal-control group, †P<0.05 
vs. insulin-control group. 
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Fig. 17 AMPK-enhanced insulin action is cholesterol dependent. Myotubes 
were treated as described in Fig. 12 in the absence or presence of exogenous 
cholesterol (βCD:Chol; 1 mM 8:1 molar ratio). GLUT4 content was determined as 
described in Methods. Values are means ±SE of GLUT4myc/nucleus 
quantification. *P<0.05 vs. respective-basal, #P<0.05 vs. control-basal, and 
†P<0.05 vs. control-insulin. 
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knockdown of the catalytic α subunits of AMPK should prevent the enhancement 
of both basal and insulin-stimulated GLUT4 translocation by DNP. Since these 
cells express α1 and α2 isoforms of AMPK, oligonucleotides against both were 
used simultaneously for knockdown. The combination of α1 and α2 isoform 
specific oligonucleotides reduced the detectable pan-AMPKα protein by 90% 
(Fig. 18a). This reduction in AMPKα was associated with an ablation of DNP-
stimulated PM cholesterol lowering as compared to the control cells transfected 
with scramble oligos (Fig. 18b). Both basal and insulin-stimulated enhancements 
in PM GLUT4 by DNP were absent in AMPK deficient cells (Fig. 18c). 
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Fig. 18 AMPK knockdown abrogated DNP-induced PM cholesterol lowering 
and increased basal- and insulin-stimulated PM GLUT4. Transfected 
myotubes were prepared and AMPK protein (a), PM cholesterol (b), and PM 
GLUT4 (c) were determined as described in Methods. Values are means ±SE of 
GLUT4myc/nucleus quantification (b). *P<0.05 vs. basal- treatment group, 
#P<0.05 vs. basal-control group, †P<0.05 vs. insulin-control group. 
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Chapter III 
 
Perspectives 
 
The studies described in the previous chapter suggest that PM cholesterol 
and cortical F-actin influence skeletal muscle glucose transport. The importance 
of these studies is of fundamental and clinical interest as they describe 
diabetogenic insults that promote membrane/cytoskeletal dysfunction which may 
be amendable for therapy. Study on the effects of exposure of skeletal muscle to 
excess FAs tested if PM cholesterol/F-actin changes could contribute to FA-
induced glucose transporter GLUT4 dysregulation in skeletal muscle. 
Furthermore this work was extended to investigate excess-nutrient stimulation of 
HBP flux and cholesterogenic reprogramming, providing preliminary evidence for 
the mechanism that may drive these PM/cytoskeletal defects in FA-induced 
resistance as well as other diabetogenic insults. Conversely, study investigating 
lipid-lowering action of AMPK suggested a beneficial influence on PM cholesterol 
balance as well as stimulating accumulation of GLUT4 at the PM and increasing 
insulin response. Although only one study was focused solely on a mechanism of 
insulin resistance, both describe the role of PM cholesterol in the regulation of 
GLUT4 trafficking. 
While the derangements that contribute to insulin resistance are certainly 
numerous and complex, work throughout the field has highlighted the detrimental 
effects of saturated FAs, and particularly palmitate, on insulin sensitivity in 
skeletal muscle. Data presented in Chapter II.A. suggest a new consideration 
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that membrane cholesterol accrual may play a contributing role in obesity-
associated insulin resistance. Mechanistically, the cholesterol-laden membrane 
compromises cortical F-actin structure, documented by several laboratories to be 
an essential feature of insulin and GLUT4 action 105, 316, 329, 330. A prediction, 
based on the myotube and animal analyses, is that in insulin-resistant humans F-
actin disruption is occurring concomitantly with PM cholesterol accrual, and this 
may play a causal role in skeletal muscle insulin resistance. 
 In the context of signaling defects, perhaps the decrease in insulin 
signaling to Akt-2 that we see induced by palmitate was not as damaging as 
would be predicted and/or not yet advanced to a level to compromise GLUT4 
regulation. As these studies progressed, an alternative hypothesis involving the 
stimulation of PKCθ by FA of was suggested. As detailed in Chapter I, this 
stimulation, results in serine phosphorylation of IRS1 and inhibition of the insulin 
signaling cascade 71, 75, 331. In the presence of FAs this kinase has been shown to 
be phosphorylated on serine residue 538. This activation loop phosphorylation 
has been shown to induce a robust activation leading to serine phosphorylation 
of its targets 332, Phosphorylation of one of these targets, IRS1 on serine residue 
1101, has been shown to directly inhibit tyrosine phosphorylation and thus induce 
insulin resistance 331. We tested this postulate in our system of palmitate-induced 
GLUT4 dysfunction, and found that, palmitate treatment resulted in a trend for an 
11% increase in phosphorylation of PKCθ on Ser538 (Fig. 19a). Furthermore, 
while there was a trend for a 73% increase in phosphorylation of IRS1 on 
Serine1101 (Fig. 19b), this was not associated with any defects in tyrosine 
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phosphorylation of IRS1 as determined by the PY20 antibody (Fig. 19c). Taken 
together these data suggest that PKCθ is unlikely to be the mediator of signaling 
defects observed in Akt-2 phosphorylation or the FA-induced insulin resistance in 
this system. This view of a non-signaling based defect in GLUT4 regulation is 
supported by recent analysis showing that insulin’s maximal effect on GLUT4 
translocation in L6-GLUT4myc myotubes occurs at insulin concentrations where 
only 5% of the total Akt pool is phosphorylated 333. Moreover, that work also 
revealed that palmitate concentrations below 300 µM did not induce substantial 
defects in insulin signaling. Therefore, this model of insulin resistance points to a 
major node of insulin resistance beyond proximal insulin signaling steps.  
 We speculate that palmitate drives PM cholesterol accrual that directly 
inhibits GLUT4 trafficking. Furthermore, it is our hypothesis that the correction of 
PM cholesterol to levels witnessed in control cells restores an insulin-stimulated 
exocytosis process, such as an F-actin-dependent event, but does not inhibit 
endocytosis, which requires a larger decrease in PM cholesterol content 334, 335. 
Alternatively, it is possible that PM cholesterol accrual increases endocytosis and 
perhaps normalization of the endocytic rate of GLUT4 retrieval accounts for its 
basal and insulin-stimulated PM accumulation with βCD. Regardless of the 
precise GLUT4 trafficking step influenced by palmitate- or βCD-induced changes 
in PM cholesterol, these data seem to unequivocally support that excess FAs 
induce PM cholesterol accrual that compromises F-actin, documented to be 
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 Fig. 19 PKCθ does not mediate Palmitate-induced Insulin resistance in L6-
GLUT4myc myotubes. Myotubes were treated as in Fig and phosphorylation of 
PKCθ (Thr538), IRS (Ser1101), and tyrosine phosphorylation of IRS1were assessed 
using phosphor-specific antibodies(a b&cb), Values are means ±SE of phospho- 
PKCθ, -IRS1 (Ser1101 or tyrosine). 
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essential for normal GLUT4 responsiveness. In further support of a cholesterol-
associated event, Shigematsu et al. found that PM caveolae, cholesterol-
enriched membrane domains, influence GLUT4 endocytosis 335. Based on these 
and the current findings, further caveolae study and detailed kinetic analyses of 
GLUT4 exocytosis and endocytosis trafficking patterns during states of insulin  
sensitivity and insulin resistance are warranted. 
 It should be noted that the high-fat diets we employed for the swine and 
mice contained 2% or 0.2% cholesterol, respectively. Interestingly, this difference 
in dietary cholesterol amount did not equate to a similar difference in skeletal 
muscle membrane cholesterol accrual. For example, the high-fat fed swine that 
consumed more cholesterol displayed a lower increase in skeletal muscle 
membrane cholesterol than that witnessed in the mice fed a high-fat diet 
containing far less cholesterol. As mammalian cells contain an intricate feedback 
system that senses the level of membrane cholesterol and modulates the 
transcription of genes that mediate cholesterol synthesis and uptake 250, it is 
likely that circulating cholesterol does not contribute to skeletal muscle 
membrane cholesterol content. Rather a scenario that we favor is that 
hyperlipidemia drives PM cholesterol accrual via cellular processes, resulting in 
GLUT4 dysregulation. Further confirming the hypothesis that excess cholesterol 
is synthesized, not acquired; inhibition of HMGR with the potent pharmacological 
inhibitor atorvistatin (ATV 0.5 µM), prevents palmitate-induced accumulation of 
PM cholesterol (Fig. 20a) and restores insulin-stimulated PM GLUT4 to control 
levels (Fig. 20b, compare bars 2, 4, and 6). It is important to note, however, that 
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Fig 20. Cholesterol lowering protects against palmitate-induced insulin 
resistance. Membrane cholesterol (a) and GLUT4myc (b) from control and 
palmitate-treated L6-GLUT4myc myotubes co-treated without or with 0.5 µM 
ATV. Values are means ±SE of membrane cholesterol (a) or GLUT4myc/nucleus 
quantification (b). Open bars, basal; closed bars, 20 min insulin stimulated. 
*P<0.05 vs. control basal group, #P<0.05 vs. control insulin group. 
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in the presence of palmitate, the ATV treatment increased basal PM GLUT4 (Fig. 
20b, bar 5). This effect was similar to that witnessed in the βCD-mediated 
cholesterol lowering. As stated previously, the basis for these gains are unclear, 
yet likely explains the correction in insulin-stimulated PM GLUT4 content. 
Regardless of the precise mechanism(s), these data show that normalizing PM 
cholesterol during palmitate exposure favorably affects PM GLUT4 content. 
 In striking similarity to our myotube findings, an approximate 40% 
reduction in insulin-stimulated skeletal muscle glucose transport has been seen 
as early as 5 weeks in C57Bl/6J mice fed a high-fat diet 307, and at the 4-week 
interval skeletal muscle insulin resistance in these animals is also suggested by a 
marked decrease in glucose disposal rate with no change in hepatic glucose 
production 308. Interestingly, insulin-stimulated Akt phosphorylation tends to be 
decreased by 4 weeks of high-fat feeding, although this effect did not reach 
statistical significance until after 8 weeks, and a similar pattern was observed in 
liver tissue 336. Ongoing studies are now specifically evaluating the temporal 
sequence of membrane/cytoskeletal and signal transduction derangements in 
skeletal muscle from high-fat fed animals. A prediction we favor is that 
membrane/cytoskeletal derangement occurs before signal dysfunction and this 
early event contributes to the initial loss of insulin sensitivity. In summary, these 
data suggest that a contributing factor in the pathogenesis of insulin resistance in 
skeletal muscle might involve an accrual of PM cholesterol and a resultant defect 
in membrane/cytoskeletal function. Interestingly, this cell-surface localized defect 
seems to concomitantly occur with insulin signal propagation impairment in the 
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L6-GLUT4myc myotube system. Nevertheless, the later derangement was not 
limiting, as correction of membrane cholesterol excess mitigates cytoskeletal 
dysfunction and GLUT4 responsiveness, while signaling remained impaired.  
 For several years our group has reported both associated and causal links 
between excess PM cholesterol, decreased cortical F-actin, and multiple 
pathophysiological insults resulting in insulin resistance11, 105, 316, 337, 338. However, 
a mechanistic link between the various diabetogenic insults and the accumulation 
of cholesterol remained elusive. Recently we found that increased glucose flux 
through the HBP, stimulated by hyperinsulinemic conditions, induces the same 
loss of F-actin and insulin sensitivity as is seen with other diabetogenic insults 
that increased PM cholesterol 299.The possibility that the diabetic milieu promotes 
PM cholesterol accrual and F-actin loss via increased HBP activity is a question 
that has become of great interest to our group, and was the focus of work 
presented in Chapter II. B. Study in 3T3-L1 adipocytes and myotubes presented 
here suggest evidence for a common mechanism of insulin resistance that is 
dependent on HBP-mediated accumulation of PM cholesterol. Hyperglycemia, 
hyperlipidemia, and hyperinsulinemia treatments resulted in trends for elevated 
PM cholesterol and O-linked glycosylation, while inducing defects in cortical F-
actin as well as insulin and GLUT4 action in both cell types. These findings are 
further confirmed by preliminary study in L6-GLUT4myc myotubes that have 
been transiently transfected with a plasmid that induces the overexpression of 
GFAT. In these cells we observed a trend for an increase (31±17% p=0.21) in O-
linked glycosylation and a reciprocal decrease (48±25% p=0.20) in cortical F-
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actin. Together these observations suggest a possible link between various 
diabetogenic insults and cholesterol accumulation. 
 A role for excess glucose flux through the HBP in insulin resistance was 
first proposed by Marshall et al. 286. In the time since this finding, multiple in vitro 
and in vivo studies have suggested that glucose flux through this pathway is 
stimulated by states of excess nutrient supply including hyperglycemia, 
hyperinsulinemia 315, and hyperlipidemia 16, 285. Further bolstering these initial 
observations, recent clinical evidence has documented that GFAT expression 
and activity is elevated in T2D patients 339, and specifically in insulin resistant 
skeletal muscle 340. Several mechanisms for the HBP mediated induction of 
insulin resistance have been proposed including activation of JNK 321, induction 
of ER stress 341, O-linked glycosylation of components within the insulin-signaling 
pathway 305, and modulation of leptin expression 342. A possibility we tested was 
that accrual of excess PM cholesterol, and the resulting induction of insulin 
resistance, is due to HBP-mediated activation of the SREBP transcription factor. 
It has been shown that SREBP is regulated by glucose, through the HBP 343. In 
support of this hypothesis, increased HBP flux has recently shown to induce the 
transactivating capacity of Sp1; 323, a transcription factor shown to promote the 
maximal transcriptional activation of SREBP-1c 326, 327. SREBP-1c is encoded 
from the SREBP-1 gene that also encodes an almost identical protein designated 
SREBP-1a. Interestingly, Weigert and colleagues reported a study linking 
palmitate with the activation of the HBP and increased Sp1 DNA binding activity 
in human myotubes 16, while Hawkins et al. described an increase in 
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intermediates of the glucosamine pathway in fat-induced insulin resistance 285. 
As SREBP-1 plays an active role in the transcriptional regulation of FA synthesis 
and, albeit to a lesser extent, cholesterol synthesis genes 253, we predict that an 
unappreciated downfall of increased SREBP-1 regulation via HBP-modified Sp1 
activity is increased cholesterol synthesis resulting in PM cholesterol accrual. In 
line with this reasoning, Yang et al. recently observed that increased hepatic 
cholesterol content resulted from increasing the activity of key enzymes of the 
HBP. These findings are confirmed by trends for elevated levels of Hmgr mRNA 
observed in L6-GLUT4myc myotubes treated under hyperinsulinemic and 
hyperlipidemic conditions, as well as the elevated PM cholesterol and depleted 
cortical F-actin levels observed in streptozotocin treated mice. Although 
preliminary at this time, collectively these findings implicate a common and 
reversible abnormality (i.e., HBP-mediated PM cholesterol accrual) that can be a 
novel target to slow the progression/worsening of insulin resistance. Future 
studies will focus on the effects of diabetogenic insults on parameters of PM, 
cytoskeletal, and GLUT4 regulation in the presence or absence of OGT.  
 Along the lines that this PM/cytoskeletal defect may be reversible, the 
study described in Chaper II.C. provides evidence that PM cholesterol levels are 
regulated by AMPK and that this membrane-based event augments regulation of 
GLUT4 by insulin. In particular, AMPK activation was found to decrease PM 
cholesterol. Strikingly, the expected AMPK-enhanced insulin-stimulated PM 
GLUT4 translocation was prevented by replenishing PM cholesterol. This 
experimental strategy did not mitigate the AMPK-regulated gain in basal PM 
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GLUT4, suggesting that AMPK regulates basal and insulin-stimulated PM GLUT4 
content by cholesterol-independent and -dependent mechanisms, respectively. 
 Of particular interest is that AMPK has been implicated in at least a portion 
(~30%) of the antidiabetic effect of exercise 344. Although numerous mechanisms 
have been suggested in the insulin-mimetic and insulin-sensitizing action of 
exercise 345, 346, these mechanisms are incompletely understood. In the context 
of our studies, the AMPK-mediated decrease in PM cholesterol accounted for a 
slight (<50%) increase in insulin response seen in cells treated with AICAR and 
DNP. Whether skeletal muscle contraction and/or exercise are associated with a 
reduction in PM cholesterol is of interest and future studies are planned to 
investigate this possibility. 
 The inability of cholesterol add-back to prevent the AMPK-associated 
increase in basal GLUT4 was unexpected. A prediction was that the insulin 
mimetic activity of AMPK stimulation entailed the reported stimulation of AS160 
231, 347, 348, yet this signaling event was not observed in the present study. 
Perhaps AS160 phosphorylation detected with the anti-phopso-Akt substrate 
(PAS) antibody failed to detect the Thr642 PAS phosphorylation motif 
demonstrated to be specifically phosphorylated in L6-GLUT4myc myotubes 
treated with AICAR; whereas it recognizes the Ser588 PAS phosphorylation motif 
that is phosphorylated in tandem with the Thr642 site in response to insulin 
stimulation 231. However, study in mouse skeletal muscle suggests the reverse 
scenario; i.e., AICAR-stimulated increases in AS160 phosphorylation occur at the 
Ser588 PAS phosphorylation motif 349. Use of pThr642 and pSer588 specific 
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antibodies and an immunoprecipitation approach to enhance examination of 
endogenous AS160 phosphorylation might demonstrate AMPK-mediated 
phosphorylation. 
 We are currently performing these studies to carefully dissect if the 
AMPK/AS160 signal mediates the basal increase in PM GLUT4. Nevertheless, 
the present findings show PM cholesterol regulation as a novel target of AMPK 
that contributes to its insulin-sensitizing action. Mechanistically, we suggest that 
this may result from the AMPK-mediated phosphorylation and subsequent 
inactivation of HMGR. Although it is also possible that AMPK may lower PM 
cholesterol via suppression of SREBP-1c expression 350-352, the rapidity of the 
DNP- and AICAR-induced decrease in PM cholesterol likely suggests an instant 
inhibition of HMGR. However, chronic AMPK stimulation may also influence PM 
cholesterol content via suppressing SREBP-1c. In any case, given the rapid 
kinetics of newly synthesized cholesterol reaching the PM (t1/2=10-20 min) 353-355 
and recycling of cholesterol between the PM and endoplasmic reticulum  (t1/2=40 
min) 244, it is entirely possible that HMGR and/or SREBP-1c suppression by 
AMPK accounts, at least in part, for the reduction in PM cholesterol. Therefore, 
we are now exploring both of these possibilities as avenues to PM cholesterol 
regulation by AMPK. 
 A second interest is that we 124 and others 334, 356 have previously 
documented that extensive ≥50% PM cholesterol depletion clearly inhibits 
endocytosis, yet smaller 20-30% reductions in PM cholesterol 124 do not. This 
suggests that small reductions in PM cholesterol increase PM GLUT4 via 
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augmenting an aspect of GLUT4 exocytosis. Detailed kinetic analyses of GLUT4 
exocytosis and endocytosis trafficking patterns are currently underway. 
Regardless of whether the elevated PM GLUT4 content results from increased 
exocytosis, decreased endocytosis, or a combination of both, increased insulin-
stimulated PM GLUT4 content is a beneficial result associated with PM 
cholesterol lowering. In the context of vesicular trafficking, perhaps the AMPK-
mediated loss of PM cholesterol does not entail a regulated decrease in 
cholesterol synthesis and a subsequent lack of cholesterol delivery to the PM as 
we suggested above, but rather reflects an accelerated internalization of 
cholesterol-enriched domains. We do not necessarily favor this possibility, yet 
such an event could account for the loss of PM cholesterol and have a similar 
beneficial effect on the GLUT4 response. For example, hydrolysis of PM 
sphingomyelin by sphingomyelinase results in the movement of cholesterol from 
the PM to intracellular compartments 357-359 and we have witnessed that this 
sphingomyelinase-induced loss in PM cholesterol enhances basal and insulin-
stimulated PM GLUT4 exocytosis 124. 
 In terms of human health, we know that insulin resistance is a progressive 
syndrome, with many associated pathologies appearing as insulin sensitivity 
worsens. We speculate that at least a portion of the beneficial effects of 
exercise/contraction, and the effects of many AMPK agonists, are mediated 
through an AMPK mechanism that counterbalances PM cholesterol accrual. In 
direct support of this notion and the findings herein; beta-sitosterol, a potent 
AMPK activator recently identified from a medicinal plant extract library, was 
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shown to lower the intracellular level of cholesterol in L6-GLUT4myc myotubes 
152. That work also demonstrated an associated increase in basal PM GLUT4, yet 
did not dissect whether the increase resulted from a PM cholesterol-dependent 
and/or -independent effect. Also, the effect of this plant sterol on insulin-
stimulated PM GLUT4 was not evaluated. Although it was demonstrated that 
pharmacological inhibition of AMPK rendered the effect of beta-sitosterol on 
increasing basal PM GLUT4 ineffective, our data would predict that this was not 
a PM cholesterol mediated event; whereas any AMPK-mediated enhancement of 
insulin-stimulated PM GLUT4 would be regulated by PM cholesterol lowering. 
Future studies should focus on elucidating the relationship of AMPK to GLUT4 
regulation and glucose transport within the context of a cholesterol-regulatory 
signaling pathway.  
 An interesting caveat to these studies is that L6-GLUT4myc myotubes 
show a trend for expressing predominately the α1 isoform of AMPK and very little 
of the α2 isoform (Fig. 21a). This is surprising in light of reports showing α2 is the 
isoform most highly expressed in skeletal muscle tissue, while the α1 isoform is 
ubiquitously expressed 173, 174. This observation prompted us to investigate the 
expression of the AMPKα subunits throughout differentiation. To our surprise, we 
found that AMPKα1 protein levels display a tendency to increase from plating to 
full differentiation (day 8-10) before a gradual decline (Fig. 21b). Conversely, 
AMPKα2 protein levels show a tendency to be initially high in the myoblasts, but 
drop precipitously through differentiation, becoming nearly undetectable (Fig. 
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21c). A trend was also found for total AMPKα protein levels to follow those of the 
α1 subunit (Fig. 19d). 
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Fig. 21 AMPKα subunits are differentially expressed in L6-GLUT4myc 
myotubes. IB analysis  of α1 and α2 isoforms in myotubes from peak 
differentiation (day 8-10) (Fig 18a). α subunit protein levels from L6-GLUT4myc 
myotube throughout differentiation (Fig 18b-d). Values are means ±SE α subunit 
protein levels. 
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Conclusions 
 As a whole these studies show PM cholesterol accrual and cortical F-actin 
loss uniformly in skeletal muscle from glucose-intolerant mice, swine, and 
humans. In vivo and in vitro dissection demonstrated this membrane/cytoskeletal 
derangement induces GLUT4 dysregulation and glucose intolerance and is 
promoted by excess FAs. Preliminary pilot studies presented here suggest 
exciting new evidence for a common mechanism of insulin resistance that is 
dependent on HBP-mediated accumulation of PM cholesterol. Parallel studies 
unveiled that the action of AMPK entailed lowering PM cholesterol that enhanced 
the regulation of GLUT4/glucose transport by insulin. In conclusion, these data 
are consistent with PM cholesterol regulation being an unappreciated aspect of 
AMPK signaling that benefits insulin-stimulated GLUT4 translocation during 
states of nutrient excess promoting PM cholesterol accrual. A schematic 
representation of these findings is shown below in Fig. 22. 
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 Fig. 22 Insulin mediated regulation of glucose transport in skeletal muscle. 
Shown above is a schematic of the findings described in this thesis. GLUT4 
trafficking is increased in response to insulin or AMPK stimulation. The increase 
in PM GLUT4 is regulated via a PM cholesterol-mediated event. Conversely, high 
fat diets/palmitate treatments lead to the accumulation of PM cholesterol and a 
distruption of cortical F-Actin, which induces GLUT4 dysregulation and inhibits 
insulin-stimulated glucose transport. Detailed discussion of each component 
shown above can be found in the previous sections. 
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Chapter IV 
 
Experimental Procedures 
 
Animals 
   Four week old, male C57/BL6J mice were obtained from Jackson 
Laboratory (Bar Harbor, ME). For the hyperlipidemic study mice were assigned to 
two groups for 4 weeks of treatment. Control mice (N=3) were fed a normal chow 
diet containing 18% kcal from protein, 78% kcal from carbohydrates, and 4% kcal 
from fat (#7017; Harlan, Indianapolis, IN). High-fat fed mice (n=3) were fed a diet 
containing 17% kcal from protein, 43% kcal from carbohydrates, and 41% kcal 
from fat (D12079B; Research Diets Inc., New Brunswick, NJ). For the 
hyperglycemic study, mice were assigned to two groups for 5-6 weeks of 
treatment. STZ mice were injected with 0.3 ml per day of 4.6 mg/ml STZ in 
peritoneal cavity for five days. Control mice were injected with saline at the same 
interval. STZ mice developed hyperglycemia at approximately one week post-
final STZ dose. Mice were maintained in hyperglycemic state for 5-6 weeks 
before sacrifice and analysis. Hindlimb muscles were dissected out and blotted 
on gauze, quickly rinsed in saline, and either immersed in 4% 
paraformaldehyde/phosphate buffered saline (PBS) (soleus) or frozen in liquid 
nitrogen (gastrocnemius). Three month old Ossabaw miniature swine were 
assigned to two groups for 55 weeks of treatment. Control swine (n=9) were fed 
standard, lean chow diet containing 22% kcal from protein, 70% kcal from 
carbohydrates, and 8% kcal from fat (TestDiet, Richmond, IN). Pigs in the lean 
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group ate 1500 kcal/day until 6 months of age, then 2500 kcal/day until sacrifice. 
Obese swine (n=9) were fed excess calorie high-fat diet. Similar to that in 
previous reports 310, 311, the high-fat feed was composed of lean chow 
supplemented with (% by weight): cholesterol 2.0, hydrogenated soybean oil 47.6 
(contains 56% trans FAs), corn oil 2.5, and sodium cholate 0.7. This mixture 
yielded a composition of 10% kcal from protein, 17% kcal from carbohydrates 
and 73% kcal from fat. Obese group pigs ate ~3000-3200 kcal/day until 6 months 
of age, then 7000-7800 kcal/day until sacrifice. All animals were housed in 
individual cages/pens and provided a 12-hr light/12-hr dark cycle. Water was 
provided ad libitum. Fasting plasma glucose and insulin were determined from 
blood samples drawn from conscious pigs to calculate the homeostatic model 
assessment (HOMA) value for insulin resistance 311. All animal protocols were 
approved by the IUSM Institutional Animal Care and Use Committee. 
 
Human biopsies  
 Percutaneous needle biopsies of the vastus lateralus were obtained from 
seven subjects (5 men/2 women; Body Mass Index [BMI] 27.9±1.7 kg/m2, [range 
22.5-34]; age 37.29±4.49 years, [range 19-53]) in whom insulin sensitivity was 
determined by hyperinsulinemic-euglycemic clamp as described 360. All subjects 
gave informed consent for these studies which were approved by the Indiana 
University-Purdue University Institutional Review Board. 
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Cell culture 
 L6-GLUT4myc culture and induction of insulin resistance. Rat L6-
GLUT4myc (generously obtained from Dr. Amira Klip, The Hospital for Sick 
Children, Toronto, Canada) were cultured as previously described 316. Myoblasts 
were maintained in α-Minimum essential medium (α-MEM) containing 5 mM 
glucose and 10% fetal bovine serum (FBS; HyClone Laboratories, Grand Island, 
NY), and differentiated into multinucleated myotubes with 2% FBS. All studies 
used myotubes between 4 and 6 days post-initiation of differentiation. 
Hyperinsulinemia induction of insulin resistance was performed by treating cells 
with 5 nM insulin for 12 hr in DMEM supplemented with 1%FBS. Hyperglycemia 
induction of insulin resistance was performed by treating cells with 25 mM insulin 
for 12 hr in DMEM supplemented with 1%FBS. Palmitate induction of insulin 
resistance was performed by treating cells with palmitate conjugated to FA-free 
bovine serum albumin (BSA; MP Biomedicals, Solon, OH) as detailed by Chavez 
et al. 83. Briefly, palmitate was dissolved in ethanol at a concentration of 75 mM. 
For each experiment this stock solution was diluted (1:25) to 3 mM in 1% FBS- 
Dulbecco’s modified Eagle’s medium (DMEM) containing 2% BSA (w/v), briefly 
sonicated, and incubated at 55°C for 10 min. Samples were then diluted to the 
appropriate concentration in 1% FBS-DMEM-2% BSA, cooled to room 
temperature, and filter sterilized. Myotubes were incubated for 15-16 hr in either 
the presence or absence of palmitate. Prior to all experiments, cells were serum 
starved for 60 minutes. All acute treatments occurred during the final 20-45 
minutes of serum starvation. To activate AMPK cells were either treated or left 
untreated for 45 or 30 min with 1 mM AICAR or 200 µM DNP, respectively. 
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During the final 20 min of treatment, cells were stimulated with 100 nM insulin or 
left in the basal state. 
 Adipocyte culture and induction of insulin resistance. Murine 3T3-L1 
preadipocytes were cultured in DMEM containing 25 mM glucose and 10% calf 
serum at 37°C in an 8% CO2 atmosphere. Confluent cultures were induced to 
differentiate into adipocytes. Adipocytes cultured/differentiated under the 
standard 25 mM glucose protocol were switched into DMEM/5.5 mM glucose 
medium containing 10% FBS for two days prior to inducing insulin resistance. 
Three experimental conditions were utilized routinely: i) control, ii) 5 nM insulin, 
and iii) 2 mM GlcN. In each of these conditions the culture medium for overnight 
induction of insulin resistance contained 1 mM pyruvate as an additional energy 
source. Overnight incubations were limited to 12 h to minimize complications due 
to effects of glucose deprivation on glucose transport 361. The three experimental 
conditions are as follows: 
 (i) Control. Control adipocytes were incubated for 12 h in DMEM/5.5 mM 
glucose medium containing 10% FBS in the absence of insulin. The 
concentration of glutamine in the incubation medium was 2 mM (referred to as 
control). 
 (ii) Insulin. Impairment of the glucose transport system was induced by 12 
h treatment of cells in DMEM/5.5 mM glucose containing 10% FBS, 5 nM insulin, 
and 2 mM glutamine (referred to as 12 h Ins). 
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 (iii) GlcN. To induce insulin resistance, adipocytes were treated with 
DMEM containing 10% FBS and 2 mM GlcN for 12 h, in the absence of glucose, 
glutamine, and insulin (referred to as 12 h GlcN). 
 
Glucose transport 
 Uptake assays were performed as previously described 316. Briefly, treated 
cells were incubated in glucose-free buffer (125 mM NaCl, 5 mM KCl, 1.8 mM 
CaCl2, 2.6 mMMgSO4, 25 mM HEPES, 2 mM pyruvate, and 2% BSA) for 30 min, 
then either left in the basal state or stimulated with 100 nM insulin for 20 min. 
Uptake was initiated with the addition of 2-deoxy-[1,2,-3H]-glucose (0.055 µCi/µl; 
PerkinElmer, Boston, MA). Nonspecific uptake was quantitated via cell-
associated radioactivity in the presence of 20 µM cytochalasin B. After 5 min, 
uptake was terminated via four quick washes with ice-cold PBS. Cells were 
solubilized in 1 N NaOH and [3H] was measured by liquid scintillation. Counts 
were normalized to total cellular protein, as determined by the Bradford method. 
 
Membrane analyses 
 L6-GLUT4myc myotubes. Crude plasma membrane fractions were 
obtained using a differential centrifugation method as detailed by Khayat et al. 
328, with slight modifications. Briefly, skeletal muscle or L6-GLUT4myc myotubes 
were washed, resuspended in HES buffer (20 mM HEPES, pH 7.4, 1 mM EDTA, 
and 255 mM sucrose containing 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 
µg/ml pepstatin, 10 µg/ml aprotinin, and 5 µg/ml leupeptin), and processed by 
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polytron homogenization (15 s) or shearing the sample through a 22-gauge 
needle 10 times, respectively. Lysates were then centrifuged at 5,000 ×g for 20 
min at 4°C. The supernatant was subjected to centrifugation at 100,000 ×g for 30 
min. The pellet was resuspended in HES buffer and assayed for protein 
(Bradford) and cholesterol (Amplex Red) content as previously described 126. 
 3T3-L1 adipocytes. Adipocyte subcellular membrane fractions were 
obtained using the differential centrifugation method previously described 362 with 
slight modification. Briefly, control and insulin-stimulated 3T3-L1 adipocytes were 
washed and resuspended in HES buffer (20 mM HEPES, pH 7.4, 1 mM EDTA 
and 255 mM sucrose containing 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml 
pepstatin, 10 µg/ml aprotinin and 5 µg/ml leupeptin). Cell lysates were prepared 
by shearing the cells through a 22-gauge needle 10 times. Lysates were then 
centrifuged at 19,000 × g for 20 min at 4°C. The intracellular membrane pellet 
was obtained by centrifugation of the resulting supernatant at 180,000 × g for 75 
min at 4°C. The plasma membrane pellet was obtained by resuspending the 
pellet from the initial 19,000 × g centrifugation in HES buffer followed by layering 
onto a 1.12 M sucrose cushion for centrifugation at 100,000 × g for 60 min. The 
plasma membrane layer was removed from the sucrose cushion and centrifuged 
at 40,000 × g for 20 min. All pelleted fractions were resuspended in a detergent-
containing lysis buffer and assayed for soluble protein content. 
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Preparation of nuclear extracts 
 Nuclear extracts were collected as previously described 363. Briefly, 3T3-
L1 adipocytes were washed with PBS and 2 ml of hypotonic buffer (10 mM 
HEPES, pH 7.4, 10 mM KCl, 1.5 mM MgCl2, 1 mM DTT containing 20 mM 
leupeptin, 2 mM pepstatin, 2 mM aprotinin and 0.5 M PMSF). Cell lysates were 
prepared by shearing the cells through a 22-gauge needle 5 times. Prepared 
lysates were centrifuged at 800 g for 10 min at 4°C. The pellet was then carefully 
dried and resuspended in 0.5 ml of buffer C (10 mM HEPES, pH 7.4, 0.42 M 
NaCl, 25% glycerol (v/v), 1.5 mM MgCl2, 0.5 mM EDTA containing 20 mM 
leupeptin, 2 mM pepstatin, 2 mM aprotinin and 0.5 M PMSF). Nuclei were then 
visualized by staining with 0.2% trypan blue. Proteins were allowed to swell out 
of the nuclei by vortexing for 15 s every 10 min for 40 min. The mixture was then 
centrifuged at full speed in a microcentrifuge at 4°C for 15 min. Supernatant was 
collected and assayed for soluble protein content. 
 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE 
analyses)  
 Total cell extracts were prepared from 100-mm dishes. Myotubes were 
washed two times with ice-cold PBS and scraped into 1 ml lysis buffer (25 mM 
Tris, pH 7.4, 50 mM NaF, 10 mM Na3P2O7, 137 mM NaCl, 10% glycerol, and 1% 
Nonidet P-40) containing 2 mM PMSF, 2 mM Na3VO4, 5 µg/ml aprotinin, 10 µM 
leupeptin, and 1 µM pepstatin A then rotated for 15 min at 4°C. Insoluble material 
was separated from the soluble extract by centrifugation for 15 min at 4°C. 
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Protein concentrations were determined via the Bradford method and equivalent 
protein amounts were loaded onto a 7.5% acrylamide gel. The resolved fractions 
were transferred to nitrocellulose (Bio-Rad, Hercules, CA). Phospho-Akt-2 was 
detected with anti-phospho-Akt-2 (Ser474) (Genscript, Piscataway, NJ). 
Phospho-IR and IRS1 were detected with a monoclonal phosphotyrosine 
antibody (PY20; Transduction Laboratories, San Diego, CA). We also used 
phosphospecific antibodies to AS160 (PAS; Cell Signaling, Danvers, MA), HMGR 
and ACC (Millipore, Temecula, CA). AMPK was detected with anti-AMPK (Cell 
Signaling Technology, Danvers, MA) OGT was detected with anti-OGT (Santa 
Cruz Biotechnology, Santa Cruz, CA) Equal protein loading was confirmed by 
Ponceau staining and by immunoblot analysis with anti-actin antibody 
(Cytoskeleton, Denver, CO). All immunoblots were labeled with IR-conjugated 
secondary antibody and analyzed via the Odyssey imaging system (LI-COR, 
Lincoln, NE). 
 
Immunocytochemistry  
 Labeling of isolated soleus muscle was performed as previously described 
316. Briefly, tissues were fixed for 2 h and then permeabilized. Paired tissue 
sections were rinsed three times in PBS and then blocked in 5% milk/PBS/0.05% 
Tween. Tissues were then incubated in anti-F-actin antibody and extensively 
washed in PBS prior to incubation for 60 min at room temperature in rhodamine 
red-X-conjugated donkey anti-mouse IgM. Tissues were again subjected to an 
extensive PBS wash and then a quick ddH2O rinse. Tissues were mounted in 
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Vectashield and analyzed via confocal microscopy (model LSM 510 NLO; Zeiss, 
Thornwood, NY). All microscope/camera settings were identical between groups. 
Labeling of myotubes was performed as previously described 316. Briefly, 
myotubes were fixed and left unpermeabilized (GLUT4myc) or permeabilized (F-
actin) in 0.2% Triton-X 100/PBS and blocked in Odyssey Blocking Buffer. The 
blocked samples were then incubated in primary antibody. GLUT4myc was 
detected with anti-cMyc (Santa Cruz Biotechnology, Santa Cruz, CA). Following 
the overnight labeling, cells were washed and incubation with infrared-conjugated 
secondary antibody. Images were collected and quantitated with the LI-COR 
infrared imaging system as previously described 316. Immunofluorescent intensity 
was normalized to intensity from Syto60, a fluorescent nucleic acid stain 
(Molecular Probes). 
 
RNA isolation and measurement using RT-PCR  
 L6-GLUT4myc myotubes were treated with or without palmitate for 16 
hours, washed twice in ice cold PBS. Cells were lysed using a Qiagen 
QIAshredder and RNA was isolated using a Qiagen RNeasy mini kit. RNA was 
reversed transcribed with the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems) for production of a RT-PCR template. Reactions were 
performed in a 96-well plate format using the ABI Prism 7000 Sequence 
Detection System (Applied Biosystems). Each reaction contained the following: 
12.5 µL of SYBR GREEN (Applied Biosystems), 500 nM of each primer, cDNA, 
and RNase free water up to a total volume of 25 µL. The ΔΔCt method of relative 
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quantification using real-time quantitative PCR was used. Data are expressed as 
the ratio of Hmgr to Gapdh using primers specific for the rat Hmgr gene (forward 
5’-TGT GGG AAC GGT GAC ACT TA-3’; reverse 5’-CTT CAA ATT TTG GGC 
ACT CA-3’) and rat Gapdh gene (forward 5’-ATG GCC AGC CTC GTC CCG 
TAG ACC AAA ATG-3’; reverse 5’-AAG TGG GCC CCG GCC TTC TCC AT-3’) 
with an annealing temperature of 60oC. 
 
ATP measurement. 
 Intracellular ATP content was measured using a luminescence ATP detection 
assay system (ATPliteTM, PerkinElmer Inc.) as we have previously described 315. 
Briefly, following experimental treatments, L6-GLUT4myc myotubes were lysed 
using a mammalian cell lysis buffer which inactivates endogenous ATPase. 
Subsequently whole cell lysate was incubated with substrate buffer and 
luminescence was detected using the SpectraMax M2 (Molecular Devices). 
Luminescence was converted to actual ATP content (nM) by use of an ATP 
standard curve. ATP concentrations were normalized for protein concentration 
determined by the Bradford method. 
 
siRNA design and transfection. 
 Three independent oligonuceotide sequences, designed and purchased 
from Ambion (Austin, TX), were tested for each of the two alpha subunit isoforms 
of AMPK or OGT. The oligonucleotides with the highest knockdown efficiency for 
α1, α2, and OGT were respectively: CGA GUU GAC UGG ACA UAA Att (siRNA 
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ID#: 194424) GCA ACU AUC AAA GAC AUA Ctt (siRNA ID#: 194794), and CAU 
UUA UGA CAA UCG AAU Att (siRNA ID#: s130675). As these cells express both 
AMPK alpha isoforms, the combination of the two nucleotides led to the greatest 
knockdown efficiency of total AMPK, while only one oligo was necessary for OGT 
knockdown studies. Ambion’s Negative Control #1 siRNA (Cat #:4635) was used 
as a control in all experiments. For all knockdown experiments cells were seeded 
as described before. Cells were first transfected at approximately 48 hr post 
seeding (or ~60% confluency). Calcium phosphate transfection protocol was 
utilized as follows, 60 pmol of siRNA was added to siRNA mix: 15 µl ddH2O, 15 
µl Buffer A (0.5 M CaCl2, 0.1 M HEPES (pH 7.0)), and 30 µl Buffer B (0.28 M 
NaCl, 0.75 mM NaH2PO4, 0.75 mM Na2HPO4, 0.05 M HEPES (pH 7.0)) and after 
10 min at room temperature, the siRNA mix was added to each well of a 12 well 
plate containing 600 µl DMEM + 5% FBS and incubated 12-16 hr. Following 12-
16 hr incubation, media was aspirated and replaced with DMEM+2% FBS. 
Additional transfection was repeated 72 hr after initial transfection. Cells were 
treated and assayed 72 hr after final transfection. 
 
Statistics  
 Values are presented as means ±SE. The significance of differences 
between means was evaluated by analysis of variance. Where differences 
among groups were indicated, the Neumann-Keuls test was used for post hoc 
comparison between groups. GraphPad Prism 4 software was used for all 
analyses. P < 0.05 was considered significant.  
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